**5. Evidence for the association between diet and asthma**

#### **5.1. Antioxidants**

been studied for a few decades. Animal models of asthma are the best characterized in terms of the inflammatory and remodeling processes. The use of gene knockout and transgenic animals and the therapeutic administration of antibodies or pharmacological antagonists/ inhibitors have helped to identify a range of pre-clinical targets for subsequent evaluation in humans. Small animal models of asthma, using mice, rats and guinea pigs, are most commonly used. Most of these models are based on active sensitization to an allergen such as OVA via the airways. *In vitro* model systems using inflammatory cells and airway-related cell types are widely used in studies on immuno-biological mechanisms of asthma. A more detailed

description of the most commonly used models of asthma can be found in Table 10.

remodeling.

remodeling.

remodeling.

prostaglandins.

prostaglandins.

MBP, cytokines, and chemokines.

of LPS treatment.

Increased serum IgE levels, histological changes in airways including cellular infiltration, mediator release, AHR, and

Increased serum IgE levels, histological changes in airways including cellular infiltration, mediator release, AHR, and

Increased serum IgE levels, histological changes in airways including cellular infiltration, mediator release, AHR, and

Bronchoconstriction, AHR and cellular infiltration.

Release of proinflammatory mediators such as histamine, tryptase, chymase, cytokines, chemokines, leukotrienes, and

Release of proinflammatory mediators such as histamine, tryptase, chymase, cytokines, chemokines, leukotrienes, and

Release of proinflammatory mediators such as ECP, EPO, EDN,

Intranasal Leukocytes (mainly neutrophils) recruitment to lung within 4 hr

Airway inflammation and AHR.

**Administration Primary Effects**

Intranasal or aerosol challenge, intrathoracic inoculation, intradermal

300 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

challenge

Intraperitoneal

Intraperitoneal

Intraperitoneal

Subcutaneous and intratracheal sensitization, aerosol challenge

**In Vitro Cell Model Cell Type Primary Response(s)**

CD34+-derived primary mast cells, cord blood mast cells, skin mast cells, lung mast cells, LAD2, LUVA , HMC-1, RBL-2H3

Bone marrow-derived mast cells, peritoneal mast

cells

AML14.3D10

Eosinophils Primary cells, EoL-1,

sensitization followed by inhalational challenge

sensitization followed by inhalational challenge

sensitization followed by inhalational challenge

**In Vivo Model Route(s) of**

OVA-induced allergic

LPS lung inflammation

House dust mite exposure

Infection by Aspergillus

Ragweed allergen exposure

Infection with Ascaris

asthma

model

fumigatus

suum

Mast cells:

Human mast cells

Rodent mast cells

The airways are continuously exposed to oxidants, either generated endogenously by various metabolic reactions (e.g. from mitochondrial respiration or released from phagocytes) or derived from exogenous sources (e.g. air pollutants and cigarette smoke). Allergen-activated inflammatory cells from asthmatic patients produce more ROS than from healthy individuals. In addition, several inflammatory mediators including histamine, lipid mediators, cytokines, chemokines, ECP, and EPO are potential stimuli for ROS production in the airways, leading to asthma exacerbation.

Deficiency of endogenous antioxidant defenses has been reported in asthma [195]. Since a diet rich in vitamin A or carotenoids, vitamin C vitamin E, and flavonoids, has been associated with a decreased prevalence of asthma, understanding the relationship between dietary antioxidants and asthma-associated inflammatory responses has been a recent focus.

#### *5.1.1. Vitamin A and carotenoids*

A systemic review and meta-analysis by Allen *et al*. has shown that dietary vitamin A intake is significantly lower in asthmatic patients than in healthy subjects [196]. Asthmatic children have a lower serum vitamin A concentration than healthy controls [197]. Supplementation of the diet with lycopene, a carotene found in tomatoes and carrots, has a protective effect against asthma development in a murine model [198].

All-trans retinoic acid (ARTA), a derivative of vitamin A, inhibits airway inflammation in asthmatic rats. ARTA inhibits total cell counts and the proportion of inflammatory cells in BALF, suppresses the expression of NF-κB and intercellular adhering molecule-1 (ICAM-1), and increases the expression of iκB [199]. Retinoid acid also downregulates the expression of Th1 and Th2 chemokines in monocytes, including macrophage-derived chemokine and IP-10, which are all important in the inflammatory process [200]. Airway smooth muscle cell migration, which contributes to the airway remodeling in chronic asthma is also inhibited by ARTA [201]. However, excessive intake of vitamin A exacerbates pulmonary hyperrespon‐ siveness in murine asthma model, suggesting that excessive vitamin A may increase the risk and severity of asthma [202].

Mechanistically, vitamin A may regulate bronchial hyperreactivity by altering the function and abundance of the muscarinic M(2) receptors in bronchial tissue [203]. Moreover, carote‐ noids may regulate activation of a variety of transcription factors. Treatment of cells exposed to oxidative stress with β-carotene suppresses oxidative stress-induced activation of NF-κB and production of IL-6, TNF, and inflammatory cytokines. Carotenoids may influence the process of apoptosis in healthy cells. While the pro-apoptotic protein Bax is downregulated after induction of external stimuli, β-carotene is able to increase expression of the antiapoptotic protein Bcl-2 in normal cells. In addition, β-carotene exhibits a pro-apoptotic effect in colon and leukemic cancer cells, and this effect occurs by a redox-dependent mechanism linked with NF-κB activity. These dual roles of vitamin A, including carotenoids, on apoptosis provide the capability of carotenoids as an effective anti-inflammatory agent in various diseases.

#### *5.1.2. Vitamin C*

Many observational studies have reported associations between reduced dietary/blood vitamin C levels and reduced lung functions. Asthmatic children undergoing an exacerbation have significant lower serum levels of vitamin C [204]. There is a positive correlation between serum vitamin C levels and asthma development in children (OR=0.72 per mg/dl, 95% CI=0.55, 0.95) [10]. Furthermore, asthma patients have significantly lower vitamin C level in both the cellular and fluid-phase fraction in induced sputum [205]. Higher maternal intake of citrus fruits rich in vitamin C during pregnancy is significantly associated with a reduced risk of allergic inflammation in the offspring [206]. Administration of vitamin C in OVA-challenged mice decreases AHR, influx of inflammatory cells in BALF and attenuates lung inflammation [207]. Similarly, high dose vitamin C supplementation significantly reduces eosinophilic infiltration in BALF and increases the Th1/Th2 cytokine secretion ratio; thus, skewing the Th1/ Th2 balance toward non-allergic Th1 immune response in asthmatic mice [208].

A randomized, placebo controlled, double-blinded crossover trial has shown that vitamin C supplementation (1500 mg/day) attenuates asthma symptoms. Moreover, exhaled nitric oxide, urinary leukotriene C4, D4, E4 and 9α, 1β-prostaglandin F2 after exercise are downregulated [209]. On the contrary, there are also studies showing no significant effect of vitamin C supplementation on asthma symptoms. For example, in a randomized, placebo-controlled, double-blind parallel group trial three hundred asthma patients provided with 1 g/day vitamin C or placebo for 6 weeks do not show any improvements of asthma symptoms [210], therefore, there is insufficient evidence from randomised-controlled trials to support the use of vitamin C for asthma treatment [211].

As its mechanism of action, vitamin C may regulate factors that can influence gene expression, apoptosis, and other cellular functions indicated in inflammation. In fact, vitamin C protects against cell death triggered by various stimuli, and major proportion of this protection is associated with its antioxidant ability [212]. Vitamin C inhibits the AP-1 activation by regu‐ lating MAPK-ERK pathway [213]. Treatment of cells exposed to UV-B irradiation with vitamin C results in a 50% decrease in JNK phosphorylation, which activates AP-1, therewith inhibiting the JNK/AP-1 signaling pathways [214]. At present, however, evidence from randomized controlled trials is insufficient to recommend a specific role for vitamin C in the treatment of asthma due to variable study design and generally poor reporting system.

#### *5.1.3. Vitamin E*

which are all important in the inflammatory process [200]. Airway smooth muscle cell migration, which contributes to the airway remodeling in chronic asthma is also inhibited by ARTA [201]. However, excessive intake of vitamin A exacerbates pulmonary hyperrespon‐ siveness in murine asthma model, suggesting that excessive vitamin A may increase the risk

302 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

Mechanistically, vitamin A may regulate bronchial hyperreactivity by altering the function and abundance of the muscarinic M(2) receptors in bronchial tissue [203]. Moreover, carote‐ noids may regulate activation of a variety of transcription factors. Treatment of cells exposed to oxidative stress with β-carotene suppresses oxidative stress-induced activation of NF-κB and production of IL-6, TNF, and inflammatory cytokines. Carotenoids may influence the process of apoptosis in healthy cells. While the pro-apoptotic protein Bax is downregulated after induction of external stimuli, β-carotene is able to increase expression of the antiapoptotic protein Bcl-2 in normal cells. In addition, β-carotene exhibits a pro-apoptotic effect in colon and leukemic cancer cells, and this effect occurs by a redox-dependent mechanism linked with NF-κB activity. These dual roles of vitamin A, including carotenoids, on apoptosis provide the capability of carotenoids as an effective anti-inflammatory agent in various

Many observational studies have reported associations between reduced dietary/blood vitamin C levels and reduced lung functions. Asthmatic children undergoing an exacerbation have significant lower serum levels of vitamin C [204]. There is a positive correlation between serum vitamin C levels and asthma development in children (OR=0.72 per mg/dl, 95% CI=0.55, 0.95) [10]. Furthermore, asthma patients have significantly lower vitamin C level in both the cellular and fluid-phase fraction in induced sputum [205]. Higher maternal intake of citrus fruits rich in vitamin C during pregnancy is significantly associated with a reduced risk of allergic inflammation in the offspring [206]. Administration of vitamin C in OVA-challenged mice decreases AHR, influx of inflammatory cells in BALF and attenuates lung inflammation [207]. Similarly, high dose vitamin C supplementation significantly reduces eosinophilic infiltration in BALF and increases the Th1/Th2 cytokine secretion ratio; thus, skewing the Th1/

Th2 balance toward non-allergic Th1 immune response in asthmatic mice [208].

A randomized, placebo controlled, double-blinded crossover trial has shown that vitamin C supplementation (1500 mg/day) attenuates asthma symptoms. Moreover, exhaled nitric oxide, urinary leukotriene C4, D4, E4 and 9α, 1β-prostaglandin F2 after exercise are downregulated [209]. On the contrary, there are also studies showing no significant effect of vitamin C supplementation on asthma symptoms. For example, in a randomized, placebo-controlled, double-blind parallel group trial three hundred asthma patients provided with 1 g/day vitamin C or placebo for 6 weeks do not show any improvements of asthma symptoms [210], therefore, there is insufficient evidence from randomised-controlled trials to support the use of vitamin

As its mechanism of action, vitamin C may regulate factors that can influence gene expression, apoptosis, and other cellular functions indicated in inflammation. In fact, vitamin C protects

and severity of asthma [202].

diseases.

*5.1.2. Vitamin C*

C for asthma treatment [211].

The body of evidence from multiple studies suggests that a positive association between asthma outcomes and vitamin E intake or serum vitamin E levels. Asthmatic children have significantly lower serum levels of vitamin E than non-asthmatic children [204, 215]. A longitudinal birth cohort study has explored association between maternal plasma vitamin E, fetus and fetal lungs growth, and childhood asthma. The findings have shown that maternal vitamin E status has a positive effect on the growth of fetus and fetal lungs during early pregnancy and better asthma outcomes during childhood [216]. Moreover, high maternal vitamin E intake during pregnancy also reduces the risk of infantile wheeze [206]. Vitamin E intake is higher in control subjects than in asthma patients [217]. However there is no rela‐ tionship found between serum vitamin E level and asthma [4, 218]. On the other hand, administration of vitamin E for 6 weeks does not have an effect on asthma features and serum immunoglobulin levels in adults [219].

Role of Vitamin E has been investigated in animal models of allergic asthma. Administration of Vitamin E to allergen-challenged mice reduces mitochondrial dysfunction, Th2 cytokines production, allergen-specific IgE, and expression of lipid mediators in lung leading to alleviation of asthmatic features [220]. Expression of IL-5 mRNA and protein in lung, and plasma IgE level are reduced after OVA sensitization and challenge compared to wild type mice in vitamin E transfer protein knockout mice [221]. Moreover, dietary supplementation with vitamin E affords variable degree of protection against ozone-induced enhanced airway response in allergen-sensitized guinea pigs [222]. However, oral α-tocopherol has no protec‐ tive effect on lung response in rat model of allergic asthma. There is no improvement in OVAinduced AHR, the inflammatory cell infiltrate and histological changes [223]. The observed opposite effects of vitamin E could be associated with the study design in an animal model of asthma. The effect of vitamin E deserves further evaluation.

Vitamin E may induce immunological effects via modulation of the functional activity of T cells and enhancing the phagocytic activity of peripheral granulocytes [224]. A derivative γtocopherol appears to be a more potent anti-inflammatory agent than α-tocopherol. It de‐ creases systemic oxidative stress, cytokine release from monocytes in asthmatic patients, and inhibits monocyte response to LPS and LPS-induced degradation of IκB and JNK activation [225]. There is a contradictory study demonstrating that γ-tocopherol elevates inflammation and ablates the anti-inflammatory benefit of the α-tocopherol by regulation of endothelial cell signals during leukocyte recruitment in experimental asthma [226]. Dietary tocopherols are taken up from the intestine and transported via the lymph to the blood and then to the liver. In the liver, α-tocopherol is transferred to plasma lipoproteins, resulting in retention of γtocopherol in tissues at 10% that of α-tocopherol. On interpreting these two contradictory results, one should consider their serum levels with caution since low plasma level of γtocopherol (1.2–7.0 µM) may act as prooxidant, while higher level of γ-tocopherol (19.5 µM at 8 days) exerts antioxidative and anti-inflammatory effects.

#### *5.1.4. Vitamin D*

Over the past several years, the role of vitamin D in immunomodulation has been studied and shown to have a significant impact on innate and adaptive immunity to infections, including the pathophysiology of allergic asthma. It has been proposed that the increase in allergy and asthma is a consequence of widespread vitamin D insufficiency which appears to be frequent in industrialized countries, reflecting the insufficient intake of diet-sourced vitamin D.

The serum vitamin D level is associated with asthma in children as well as adults. A random‐ ized, placebo controlled clinical study with 1024 children suffering from mild-to-moderate persistent asthma has shown that Vitamin D deficiency ias associated with a higher rate of severe asthma [227]. There is a significant positive correlation between forced vital capacity percent predicted and serum vitamin D level children with asthma. Moreover, 91.6% of these asthmatic children are not sufficient in serum vitamin D level [228]. Low level of vitamin D in serum are also associated with increased hyperresponsiveness and reduced glucocorticoid response in adults with asthma [229]. These studies have indicated that the low serum vitamin D level is related to reduced lung function and higher risk of asthma. Reduced the risk of asthma exacerbation triggered by acute respiratory tract infection is observed in a vitamin D supplementation [230]. Higher consumption of vitamin D during pregnancy may reduce the risk of childhood wheeze and asthma.

One possible mechanism of vitamin D's protective effect against asthma can be that it inhibits the maturation process of dendritic cells by suppressing the expression of costimulatory molecules HLA-DR, CD86, CD80, the maturation marker CD83, and IL-12 which are important for the recruitment of Th1 cells [231]. Vitamin D also upregulates the expression of IL-10 receptor in dendritic cells, which is an anti-inflammatory cytokine. In addition, it can promote the production of FoxP3 positive and IL-10 positive regulatory T cells, and induce the release of IL-10, TGF-β and CTLA-4 [232]. Furthermore, it may reverse steroid-resistance in asthmatic patients through induction of IL-10 secreting T-regulatory cells [233], and vitamin D has been shown to regulate expression of many genes in ASM cells, including genes previously implicated in asthma predisposition and pathogenesis [234].

#### **5.2. Flavonoids**

Flavonoids interfere with oxidation of lipids and other molecules and this strong antioxidative property makes them protective against airway diseases linked to oxidative stress. In fact, several epidemiologic studies suggest the beneficial effects of flavonoids on asthma. A population-based case-control study has shown that apple consumption and red wine intake are inversely associated with asthma prevalence or severity, perhaps due to a protective effect of flavonoids [18]. Moreover, a 30-year longitudinal epidemiological study has reported that the incidence of asthma is lower in populations with higher intake of flavonoids [235].


**Table 11.** Common dietary flavanoids.

In the liver, α-tocopherol is transferred to plasma lipoproteins, resulting in retention of γtocopherol in tissues at 10% that of α-tocopherol. On interpreting these two contradictory results, one should consider their serum levels with caution since low plasma level of γtocopherol (1.2–7.0 µM) may act as prooxidant, while higher level of γ-tocopherol (19.5 µM at

Over the past several years, the role of vitamin D in immunomodulation has been studied and shown to have a significant impact on innate and adaptive immunity to infections, including the pathophysiology of allergic asthma. It has been proposed that the increase in allergy and asthma is a consequence of widespread vitamin D insufficiency which appears to be frequent in industrialized countries, reflecting the insufficient intake of diet-sourced vitamin D.

The serum vitamin D level is associated with asthma in children as well as adults. A random‐ ized, placebo controlled clinical study with 1024 children suffering from mild-to-moderate persistent asthma has shown that Vitamin D deficiency ias associated with a higher rate of severe asthma [227]. There is a significant positive correlation between forced vital capacity percent predicted and serum vitamin D level children with asthma. Moreover, 91.6% of these asthmatic children are not sufficient in serum vitamin D level [228]. Low level of vitamin D in serum are also associated with increased hyperresponsiveness and reduced glucocorticoid response in adults with asthma [229]. These studies have indicated that the low serum vitamin D level is related to reduced lung function and higher risk of asthma. Reduced the risk of asthma exacerbation triggered by acute respiratory tract infection is observed in a vitamin D supplementation [230]. Higher consumption of vitamin D during pregnancy may reduce the

One possible mechanism of vitamin D's protective effect against asthma can be that it inhibits the maturation process of dendritic cells by suppressing the expression of costimulatory molecules HLA-DR, CD86, CD80, the maturation marker CD83, and IL-12 which are important for the recruitment of Th1 cells [231]. Vitamin D also upregulates the expression of IL-10 receptor in dendritic cells, which is an anti-inflammatory cytokine. In addition, it can promote the production of FoxP3 positive and IL-10 positive regulatory T cells, and induce the release of IL-10, TGF-β and CTLA-4 [232]. Furthermore, it may reverse steroid-resistance in asthmatic patients through induction of IL-10 secreting T-regulatory cells [233], and vitamin D has been shown to regulate expression of many genes in ASM cells, including genes previously

Flavonoids interfere with oxidation of lipids and other molecules and this strong antioxidative property makes them protective against airway diseases linked to oxidative stress. In fact, several epidemiologic studies suggest the beneficial effects of flavonoids on asthma. A population-based case-control study has shown that apple consumption and red wine intake are inversely associated with asthma prevalence or severity, perhaps due to a protective effect

8 days) exerts antioxidative and anti-inflammatory effects.

304 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

*5.1.4. Vitamin D*

risk of childhood wheeze and asthma.

**5.2. Flavonoids**

implicated in asthma predisposition and pathogenesis [234].

Beyond antioxidative effects, flavonoids inhibit the release of histamine and other preformed granule associated mediators by inhibiting the activation of basophils and mast cells [66]. Flavonoids inhibit synthesis of IL-4, IL-13, and CD40 ligand but initiate generation of new phospholipid-derived mediators. One of the well-characterized flavonoids, quercetin, inhibits eosinophilic secretion of Charcot-Leyden crystal protein and ECP in a concentration-depend‐ ent manner. Very recently, Li *et al*. demonstrated that apigenin exhibits an anti-inflammatory activity in a murine asthma model and can switch the immune response to allergens toward the Th1 profile. These findings suggest that flavonoids are anti-allergenic and anti-inflamma‐ tory agents effective in treating/preventing asthma.

Vascular changes are one of the major components of asthmatic pathogenesis. These changes include an increase in vascular permeability, vascular dilation/engorgement, and vasculogen‐ esis/angiogenesis. Flavonoids and their related compounds have been shown to modulate expression of HIF-1, VEGF, matrix metalloproteinases (MMPs), and epidermal growth factor receptor but also inhibit NF-κB, PI3K/Akt, and ERK1/2 signaling pathways [236]. These observations suggest that flavonoids as well as their related compounds inhibit certain steps of angiogenesis including cell migration, microcapillary tube formation, and MMP expression.

Many flavonoids have been tested for their anti-asthma effect. Quercetin decreases the eosinophil recruitment, reduces IL-5 and IL-4 levels, and inhibits NF-κB activation in BALF in OVA-induced mouse model [237]. It also regulates Th1/Th2 balance by enhancing IFN-γ and decreasing IL-4 levels in mouse asthma model [179]. Naringenin alleviates airway inflamma‐ tion and reactivity by decreasing serum total IgE level and IL-4, IL-13 level in BALF and inhibiting NF-κB activity [78]. Licorice is a Traditional Chinese Medicine, which contain many flavonoids. Flavonoids extracted from licorice attenuates LPS-induced acute pulmonary inflammation by inhibiting inflammatory cells infiltration and inflammatory mediator release [238]. Neutrophils, macrophages and lymphocytes accumulation in BALF, lung TNF and IL-1β mRNA expression and lung myeloperoxidase activity are reduced; whereas BALF superoxide dismutase activity is increased [238]. Flavonoids from red algae decrease eosino‐ phil infiltration, levels of TNF, IL-4 and IL-5 in BALF, airway luminal narrowing, AHR and level of allergen-specific IgE in the serum [239]. A complex mixture of bioflavonoids derived from purple passion fruit peel extract supplemented to asthma patients in a randomized, placebo-controlled, double-blinded trial alleviates asthma clinical symptoms, including FVC and FEV1 [240].

#### **5.3. Resveratrol**

Resveratrol scavenges intracellular ROS by inducing and stabilizing antioxidant enzymes such as catalase, SOD, and glutathione peroxidase hemoxygenase. In addition to its reducing properties, resveratrol has been shown to attenuate inflammation via inhibition of prosta‐ glandin production [241] and to decrease the phosphorylation of ERK1/2, COX-2 activity, and activity of various transcription factors including NF-κB, STAT3, HIF-1α, and β-catenin [236]. Resveratrol also inhibits protein kinases (e.g. src, PI3K, JNK, and Akt) and the production of inflammatory mediators (e.g. IFN-γ, TNF, COX-2, iNOS, CRP and various interleukins). Recent studies have reported that resveratrol activates sirtuin1 (SIRT1) which is modulates apoptosis and has been shown to increase longevity in some experimental systems [242]. SIRT1 modulates poly (ADP-ribose) polymerase-1 (PARP-1) activity upon DNA damage. Activation of SIRT1 by resveratrol leads to a decrease in PARP-1 activity and promotes cell survival, which can attenuate the inflammatory reaction. We investigated the effects of resveratrol on human mast cell activation in comparison to the anti-allergic drug tranilast. The results show that resveratrol inhibits mast cell degranulation, cytokine, chemokine and leukotriene release, and is more efficacious than tranilast [316].

Resveratrol is able to modulate innate immune response by inhibiting expression of costimu‐ latory molecules (CD80 and CD86) and major histocompatibility complex classes I and II in bone marrow-derived dendritic cells and inhibit angiogenesis pathway that is mediated through expression of MMPs, VEGF, cathepsin D, ICAM-1, and E-selectin [236]. These findings suggest that resveratrol can be a very attractive compound for preventing/treating asthma since this compound displays multiple therapeutic effects, showing antioxidative, antiinflammatory, immune modulating, and vascular protective property.

Resveratrol has been shown to inhibit the airway inflammation and hyperresponsiveness in OVA-induced mouse asthma by reducing eosinophil/neutrophils infiltration, the levels of IL-4 and IL-5 in plasma and BALF [81]. It can modulate Th1/Th2 balance, polarization of naive CD4+ T cells to the Th2 phenotype, and the expression of Th2 regulatory transcription factor, GATA-3 [81]. It also inhibits cytokine release in vitro by alveolar macrophages from patients with COPD, including IL-8 and GM-CSF [186].

#### **5.4. Selenium**

tion and reactivity by decreasing serum total IgE level and IL-4, IL-13 level in BALF and inhibiting NF-κB activity [78]. Licorice is a Traditional Chinese Medicine, which contain many flavonoids. Flavonoids extracted from licorice attenuates LPS-induced acute pulmonary inflammation by inhibiting inflammatory cells infiltration and inflammatory mediator release [238]. Neutrophils, macrophages and lymphocytes accumulation in BALF, lung TNF and IL-1β mRNA expression and lung myeloperoxidase activity are reduced; whereas BALF superoxide dismutase activity is increased [238]. Flavonoids from red algae decrease eosino‐ phil infiltration, levels of TNF, IL-4 and IL-5 in BALF, airway luminal narrowing, AHR and level of allergen-specific IgE in the serum [239]. A complex mixture of bioflavonoids derived from purple passion fruit peel extract supplemented to asthma patients in a randomized, placebo-controlled, double-blinded trial alleviates asthma clinical symptoms, including FVC

306 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

Resveratrol scavenges intracellular ROS by inducing and stabilizing antioxidant enzymes such as catalase, SOD, and glutathione peroxidase hemoxygenase. In addition to its reducing properties, resveratrol has been shown to attenuate inflammation via inhibition of prosta‐ glandin production [241] and to decrease the phosphorylation of ERK1/2, COX-2 activity, and activity of various transcription factors including NF-κB, STAT3, HIF-1α, and β-catenin [236]. Resveratrol also inhibits protein kinases (e.g. src, PI3K, JNK, and Akt) and the production of inflammatory mediators (e.g. IFN-γ, TNF, COX-2, iNOS, CRP and various interleukins). Recent studies have reported that resveratrol activates sirtuin1 (SIRT1) which is modulates apoptosis and has been shown to increase longevity in some experimental systems [242]. SIRT1 modulates poly (ADP-ribose) polymerase-1 (PARP-1) activity upon DNA damage. Activation of SIRT1 by resveratrol leads to a decrease in PARP-1 activity and promotes cell survival, which can attenuate the inflammatory reaction. We investigated the effects of resveratrol on human mast cell activation in comparison to the anti-allergic drug tranilast. The results show that resveratrol inhibits mast cell degranulation, cytokine, chemokine and leukotriene release, and

Resveratrol is able to modulate innate immune response by inhibiting expression of costimu‐ latory molecules (CD80 and CD86) and major histocompatibility complex classes I and II in bone marrow-derived dendritic cells and inhibit angiogenesis pathway that is mediated through expression of MMPs, VEGF, cathepsin D, ICAM-1, and E-selectin [236]. These findings suggest that resveratrol can be a very attractive compound for preventing/treating asthma since this compound displays multiple therapeutic effects, showing antioxidative, anti-

Resveratrol has been shown to inhibit the airway inflammation and hyperresponsiveness in OVA-induced mouse asthma by reducing eosinophil/neutrophils infiltration, the levels of IL-4 and IL-5 in plasma and BALF [81]. It can modulate Th1/Th2 balance, polarization of naive CD4+ T cells to the Th2 phenotype, and the expression of Th2 regulatory transcription factor, GATA-3 [81]. It also inhibits cytokine release in vitro by alveolar macrophages from patients

inflammatory, immune modulating, and vascular protective property.

and FEV1 [240].

**5.3. Resveratrol**

is more efficacious than tranilast [316].

with COPD, including IL-8 and GM-CSF [186].

Selenium is an important molecule in both innate and adaptive immune responses. It stabilizes activated platelets by inhibiting platelet aggregation and secretion of adenine nucleotide, thus possibly blocking the release of acrachidonic acid from platelet membrane [243]. In asthma, platelets participate by acting as inflammatory cells, by releasing mediators, spasmogens and/ or by interacting with other inflammatory cell types [168]. Selenium affects the expression of endothelial cell adhesion molecules, E-selectin, P-selectin, ICAM-1, VCAM-1, and ELAM-1, which are crucial in the inflammatory process for recruitment of inflammatory cells into the target tissue [244].

Some studies have reported that asthma patients have lower selenium level in platelets and serum compared to healthy controls [245, 246]. While others studies have found no relationship between serum selenium level and asthma in Japanese and Europe populations [247, 248]. Selenium supplementation studies in mouse OVA-induced asthma models have shown that selenium has some protective effects on asthma-associated inflammation. Mice with decreased and increased levels of selenium intake show lower cytokine levels, airway inflammatory cell infiltration, serum anti-OVA IgE, airway hyperreactivity, and phosphorylated STAT-6 levels in the lung compared to medium selenium intake [249]. Selenium supplementation does not show any clinical benefit in adult asthma patients [250].

Despite the data showing positive effects of selenium on some of the pathologies associated with asthma, there are still some conflicting findings of selenium supplementation in animal and human studies. Thus the issue regarding selenium is not conclusive.

#### **5.5. Avenanthramides**

Avenanthramides (Avns) are extracted from oats and those synthetically prepared exhibit potent antioxidant properties *in vitro* and *in vivo*. The antioxidant activity of Avns is 10–30 times greater than that of oats' other phenolic antioxidants such as vanillin and caffeic acid. Avn-C, one of the three major Avns of oats, often comprises about one-third of the total concentration of Avns in oat grain (although the relative proportion of Avns is highly variable), it has the highest antioxidant activity *in vitro*. By far, these Avns constitute the major phenolic antioxidants present in the oat kernel. The antioxidant activity of Avn-enriched extract of oats has been investigated in laboratory animals. Supplementing the diet of rats at 100 mg/kg diet (providing about 20 mg Avns/kg body weight) has been reported to increase superoxide dismutase (SOD) activity in skeletal muscle, liver, and kidneys, and to enhance glutathione peroxidase activity in heart and skeletal muscles [251]. Supplementation at 200 mg/kg diet, which provides about 40 mg Avns/kg body weight in rats, attenuated the exercise-induced production of ROS [251].

In addition to demonstrating antioxidant activity, Avn compounds may also interact with cellular components, through their interactions with the molecular and signaling pathways that govern cellular responses during inflammation. Using the human aortic endothelial cell (HAEC) culture system, the potentially beneficial health effects of oat Avns was found to be mediated via modulation of the cellular and molecular processes that are known to play an important role in the inflammation of arteries and the development of atherosclerosis [251]. They have been shown to inhibit vascular endothelial cell expression of adhesion molecules, including ICAM-1, VCAM-1, and E-selectin. Suppression of these adhesion molecules resulted in inhibition of monocyte adhesion to HAEC monolayers and reduced production of several inflammatory cytokines and chemokines, including IL-6, IL-8, and MCP-1, the inflammatory components involved in fatty streak formation in arteries. The production of proinflammatory cytokines, chemokines, and adhesion molecules by endothelial cells has been shown to be regulated by redox-sensitive signal transduction involving nuclear transcription factor NF-κB. The above-observed effects of Avns on HAEC and other cells are reported to be mediated through inhibition of NF-κB. More recently, dihydroavenanthramide (DHAv), a synthetic analog of Avn, has been shown to protect pancreatic β-cells from damage via inhibition of NFκB. In a series of experiments, Guo *et al*. determined that suppression of the expression of NFκB activity by Avns is mediated via inhibition of the phosphorylation of IKK and iκB, and by suppression of proteasome activity in endothelial cells [252]. A study by Sur *et al*. demonstrated anti-inflammatory activity of Avns in skin, inhibiting the degradation of IκB-α in human keratinocytes which correlates with decreased activation of NF-κB and subsequent reduction in IL-8 release [253]. Topical application mitigates skin inflammation in murine model of contact hypersensitivity and neurogenic inflammation and reduces pruritogen-induced scratching in murine itch model [253]. Taken together these observations suggest that Avns are potent anti-inflammatory agents with a potential application in asthma treatment.

#### **5.6. Herbal preparations**

Herbs have been used to treat airway diseases including asthma for thousands years in many nations, especially in Asian and African countries. In recent decades, some Chinese, Japanese, Indian, and African herbs have been tested for their anti-asthmatic effects.

#### *5.6.1. Boswellia serrata*

Boswellia serrata, Indian frankincense, is commonly found in many regions of the world, such as South Asia, Northern Africa, and Middle East. Traditional medicine using extract made from sap, has long been used to treat inflammatory diseases [204]. These extracts contain resin, amino acids, phenols, terpenes, polysaccharides [205] and β-boswellic acid the major active anti-inflammatory component [206].

Extract of Boswellia Serrata or β-boswellic acid has been reported to inhibit hypersensitivity reactions by regulating both the humoral and cellular immune systems They decrease primary antibody synthesis, inhibit polymorphonuclear leukocyte proliferation and infiltration, enhance the phagocytotic function of macrophages, and suppress the classical and alternate complement pathways [254, 255] and suppress the inflammation process, one of the critical pathological features in asthma. It has been shown that β-boswellic acid inhibits the production of proinflammatory cytokines, including TNF, IL-1, IL-2, IL-6, IL-12 and IFN-γ by suppressing the activation of NF-κB [256]. It also inhibits histamine release from mast cells challenged with G protein stimulator c48/80 in a dose-dependent manner [257]. β-boswellic acid can downregulate the synthesis of prostaglandins by inhibiting COX-1 in intact human platelets [258]. The synthesis of 5-hydroxyeicosatetraenoic acid (5-HETE) and leukotriene B4 from rat peritoneal polymorphonuclear leukocytes, which contribute to bronchoconstriction, and increased vascular permeability, are reduced by Boswellia Serrata extract as a result of 5-LO inhibition [259]. These results suggest that Boswellia Serrata might be effective in controlling the inflammation process and contraction of airway smooth muscle in asthmatic condition by inhibiting enzymes required for production of proinflammatory mediators and bronchocon‐ strictor.

Boswellia serrata

important role in the inflammation of arteries and the development of atherosclerosis [251]. They have been shown to inhibit vascular endothelial cell expression of adhesion molecules, including ICAM-1, VCAM-1, and E-selectin. Suppression of these adhesion molecules resulted in inhibition of monocyte adhesion to HAEC monolayers and reduced production of several inflammatory cytokines and chemokines, including IL-6, IL-8, and MCP-1, the inflammatory components involved in fatty streak formation in arteries. The production of proinflammatory cytokines, chemokines, and adhesion molecules by endothelial cells has been shown to be regulated by redox-sensitive signal transduction involving nuclear transcription factor NF-κB. The above-observed effects of Avns on HAEC and other cells are reported to be mediated through inhibition of NF-κB. More recently, dihydroavenanthramide (DHAv), a synthetic analog of Avn, has been shown to protect pancreatic β-cells from damage via inhibition of NFκB. In a series of experiments, Guo *et al*. determined that suppression of the expression of NFκB activity by Avns is mediated via inhibition of the phosphorylation of IKK and iκB, and by suppression of proteasome activity in endothelial cells [252]. A study by Sur *et al*. demonstrated anti-inflammatory activity of Avns in skin, inhibiting the degradation of IκB-α in human keratinocytes which correlates with decreased activation of NF-κB and subsequent reduction in IL-8 release [253]. Topical application mitigates skin inflammation in murine model of contact hypersensitivity and neurogenic inflammation and reduces pruritogen-induced scratching in murine itch model [253]. Taken together these observations suggest that Avns are potent anti-inflammatory agents with a potential application in asthma treatment.

308 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

Herbs have been used to treat airway diseases including asthma for thousands years in many nations, especially in Asian and African countries. In recent decades, some Chinese, Japanese,

Boswellia serrata, Indian frankincense, is commonly found in many regions of the world, such as South Asia, Northern Africa, and Middle East. Traditional medicine using extract made from sap, has long been used to treat inflammatory diseases [204]. These extracts contain resin, amino acids, phenols, terpenes, polysaccharides [205] and β-boswellic acid the major active

Extract of Boswellia Serrata or β-boswellic acid has been reported to inhibit hypersensitivity reactions by regulating both the humoral and cellular immune systems They decrease primary antibody synthesis, inhibit polymorphonuclear leukocyte proliferation and infiltration, enhance the phagocytotic function of macrophages, and suppress the classical and alternate complement pathways [254, 255] and suppress the inflammation process, one of the critical pathological features in asthma. It has been shown that β-boswellic acid inhibits the production of proinflammatory cytokines, including TNF, IL-1, IL-2, IL-6, IL-12 and IFN-γ by suppressing the activation of NF-κB [256]. It also inhibits histamine release from mast cells challenged with G protein stimulator c48/80 in a dose-dependent manner [257]. β-boswellic acid can downregulate the synthesis of prostaglandins by inhibiting COX-1 in intact human platelets [258].

Indian, and African herbs have been tested for their anti-asthmatic effects.

**5.6. Herbal preparations**

*5.6.1. Boswellia serrata*

anti-inflammatory component [206].

Preliminary clinical investigation has shown Boswellia Serrata's potential therapeutic effect on asthma. In a double-blind, placebo-controlled clinical study [260], 40 patients took 300 mg of extract daily for six weeks, while a control group received a lactose placebo for the same period of time. Lung and immune functions were recorded, including dyspnoea, rhonchi, frequency of attacks, FEV1, FVC, peak expiratory flow rate (PEFR), eosinophil count and erythrocyte sedimentation rate. In the treatment group 70% of patients and 27% in the control group showed improvement in terms of recorded physical symptoms and signs. These results suggest that Boswellia Serrata extract has potential benefit for asthma patients, although the age for control and treatment group was not perfectly matched. However, there is not enough evidence to draw a conclusion on the potential use of Boswellia Serrata for treating asthma in human.

#### *5.6.2. Bromelain*

Bromelain is an extract from the pineapple stem, Ananas comosus, containing a mixture of cysteine proteases, peroxidase, acid phosphatase, protease inhibitors, and calcium, with cysteine proteases being the main functional components [214].

Bromelain modulates immune responses both *in vitro* and *in vivo*. In *vitro*, it downregulates mRNA expression of IL-2, IL-4, and IFN-γ in T cells induced by phorbol myristate acetate (PMA), with the mechanism thought to be the inhibitionof p21ras and subsequent ERK-2 [261, 262]. In a study using peripheral blood mononuclear cells (PBMC), Bromelain decreases the expression of migration/activation related cell surface markers on leukocyte by proteolysis, including CD14, CD16, CD21, CD25, CD44, CD45RA, CD62L [263]. In addition, it can dosedependently reduce CD25 expression in anti-CD3 antibody-stimulated CD4+ T cells, which is upregulated when T cells are activated in inflammation, autoimmunity and allergy [264]. These results indicate that Bromelain may regulate inflammatory process by interfering the migration and activation of immune cells, primarily T cells. *In vivo*, Bromelain may inhibit IgG production and decrease IL-2 gene transcription in spleen, and significantly reduce blood CD4+ T cell count [262]. In addition, it downregulates IFN-γ mRNA expression in spleen [265]. These results indicate that Bromelain has regulatory effects on the adaptive immunity, principally by targeting T cell responses.

Bromelain administration via intraperitoneal injection alleviates some of the features of airway inflammation in the OVA-induced murine asthma model. It reduces the total numbers of leukocytes, eosinophils, CD4+ and CD8+ T cells in BALF, and decreases IL-13 concentration, which is a critical mediator for AHR in asthma [266]. In separate study, oral supplementation has been shown to suppress airway methacholine sensitivity, decrease IL-13 level, and eosinophils, CD19+ B cells and CD8+ T cells counts in BAL [267]. These results suggest that Bromelain modulates airway reactivity by altering the presence of leukocytes in airway, which is consistent with the *in vitro* results mentioned above. However, there is no clinical report available on the use of Bromelain against asthma so far.

#### *5.6.3. Butterbur (Petasites hybridus)*

Butterbur is a member of the perennial sunflower family found in Europe and northern Asia. The ancient Greeks used butterbur roots to treat airway diseases and alleviate bronchial spasms [268].

Fukinolic acid

Petasin

Extract from the flower bud, leaves and root have been shown to inhibit β-hexosaminidase release, leukotriene C4/D4/E4 synthesis, and TNF production from IgE-sensitized RBL-2H3 cell [223]. A group of Japanese researchers reported that Japanese butterbur contains multiple active compounds including two eremophilane-type sesquiterpenes, six polyphenolic com‐ pounds, and two triterpene glycosides [223], and based on its inhibitory activity on mast cell degranulation, fukinolic acid is believed to be the most active component [269]. Another active component petasin, can reduce leukotriene and ECP production from eosinophils activated by platelet-activating factor (PAF) or C5a via suppression of cytosolic phospholipase A2 (cPLA2) activity, decreasing intracellular calcium concentration and inhibiting 5-LO translo‐ cation from the cytosol to nuclear membrane [270]. Pepsin inhibits leukotriene production from macrophages [271] and suppresses bronchial constriction induced by histamine, carba‐ chol, KCl and leukotriene D4 in isolated guinea pig trachea [272]. In the OVA murine model, butterbur extract given intranasally together with antigen challenge has been shown to inhibit airway inflammation induced by OVA and hyperresponsiveness to aerosolized methacholine, reduce eosinophil count and decrease Th2 cytokine production including IL-4, IL-5 and RANTES in BALF [227]. These results suggest that Butterbur may have inhibitory effects on proinflammatory mediator release from a broad range of immune cells.

In 2003, a prescription-based Butterbur extract was approved in Switzerland for the treatment of seasonal allergic rhinitis and in response some researchers have tested Butterbur extract for the treatment of asthma. Ziolo *et al* conducted an open clinical study on its effects on bronchial reactivity in asthma patients. Provided orally in a single dose for three time periods patients show significant improvement on FEV1, especially subjects those in longer treatment group[273]. In another randomized, double-blind, placebo-controlled clinical study, results have shown that the signs of asthma are significantly suppressed by Butterbur treatment including FEV1, exhaled NO, serum ECP and peripheral blood eosinophil count, suggesting Butterbur reduces some of the inflammatory markers associated with allergic respiratory inflammation [274], However, some long term adverse side effects have ben reported including abdominal pain, flatulence, and sneezing in pediatric patients and hair loss, cough, dyspnea, and severe depression for adult patients [230]. More studies with larger sample size are needed for the evaluation of Butterbur's clinical use on asthma.

#### *5.6.4. Curcumin*

These results indicate that Bromelain may regulate inflammatory process by interfering the migration and activation of immune cells, primarily T cells. *In vivo*, Bromelain may inhibit IgG production and decrease IL-2 gene transcription in spleen, and significantly reduce blood

Bromelain administration via intraperitoneal injection alleviates some of the features of airway inflammation in the OVA-induced murine asthma model. It reduces the total numbers of

which is a critical mediator for AHR in asthma [266]. In separate study, oral supplementation has been shown to suppress airway methacholine sensitivity, decrease IL-13 level, and

Bromelain modulates airway reactivity by altering the presence of leukocytes in airway, which is consistent with the *in vitro* results mentioned above. However, there is no clinical report

Butterbur is a member of the perennial sunflower family found in Europe and northern Asia. The ancient Greeks used butterbur roots to treat airway diseases and alleviate bronchial

COOH

CH3 CH3

Extract from the flower bud, leaves and root have been shown to inhibit β-hexosaminidase release, leukotriene C4/D4/E4 synthesis, and TNF production from IgE-sensitized RBL-2H3 cell [223]. A group of Japanese researchers reported that Japanese butterbur contains multiple active compounds including two eremophilane-type sesquiterpenes, six polyphenolic com‐ pounds, and two triterpene glycosides [223], and based on its inhibitory activity on mast cell degranulation, fukinolic acid is believed to be the most active component [269]. Another active component petasin, can reduce leukotriene and ECP production from eosinophils activated

O

HOOC

O

O

CH3

CH3

HO

<sup>O</sup> OH

O

CH3

CH2

and CD8+

B cells and CD8+

310 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

available on the use of Bromelain against asthma so far.

HO

HO

 T cell count [262]. In addition, it downregulates IFN-γ mRNA expression in spleen [265]. These results indicate that Bromelain has regulatory effects on the adaptive immunity,

T cells in BALF, and decreases IL-13 concentration,

T cells counts in BAL [267]. These results suggest that

OH

CD4+

principally by targeting T cell responses.

leukocytes, eosinophils, CD4+

*5.6.3. Butterbur (Petasites hybridus)*

eosinophils, CD19+

spasms [268].

Fukinolic acid

Petasin

Curcumin is a yellow polyphenol compound, extracted from the rhizomes of *Curcuma longa* [231]. In ancient time, curcumin containing turmeric plants were widely used to treat swelling and wounds in Southern Asia [275].

#### Curcumin

Many pharmacological effects of curcumin have been reported, including antioxidative, antiinflammatory and antimicrobial activities [276]. In terms of its antioxidative effects, curcumin is thought to be more potent than vitamin E [277] with the mechanism including downregu‐ lation of NO production, scavenging free radicals, and inducing heme oxygenase-1 to repair the oxidative damage caused by free radicals [278-280]. Curcumin can inhibit the production of proinflammatory cytokines such as IL-1β and IL-8, suppress inducible iNOS and NO production, and modulate steroid activity. It's effect on steroid activity may be the result of inhibition of NF-κB through blocking IKK activity [281-284].

During allergic inflammation, curcumin may modulate both early and late phase responses by altering Th2 responses. In a murine latex-induced allergy model, characterized by an increased serum total IgE and latex specific IgG1, elevated peripheral blood eosinophils count, and enhanced lung tissue IL-4, IL-5 and IL-13, intragastric curcumin administration reduces lung inflammation. Protein expression of costimulatory molecules CD80, CD86, and OX40- Ligand, and RNA expression of MMP-9, ornithine aminotransferase (OAT), and thymic stromal lymphopoietin (TSLP) in antigen-presenting cells are all decreased. These results suggest that curcumin may disrupt antigen presentation, so that has potential therapeutic value on allergen triggered airway inflammation [285].

Curcumin has been shown to have anti-asthmatic effects in both *in vivo* and *in vitro* studies. In OVA-induced asthma model in guinea pigs, curcumin treatment during OVA sensitization or following antigen challenge shows significant protective effects through attenuation of bronchial constriction and hyperreactivity [286]. This indicates curcumin has both preventive and therapeutic effects on asthma. In another study in an OVA-induced murine asthma model, curcumin's anti-asthmatic function is attributed to the suppression of iNOS and subsequent NO production, inhibition of inflammatory cytokine synthesis and downregulation of eosinophil recruitment to airway [91]. *In vitro*, curcumin supplementation inhibits IgE/antigen activation of mast cells through the principal activation pathway mediated by FcεRI directly inhibiting Syk kinase phosphorylation, which is critical for the propagation of signaling cascade. Subsequently, the phosphorylation of MAP kinases including p38, ERK 1/2 and JNK are supressed, which are crucial for gene transcription and production of proinflammatory cytokines [287]. In addition, curcumin inhibits HDM-induced lymphocyte proliferation and production of IL-2, IL-4, IL-5, and GM-CSF by lymphocytes from asthma patients [246]. These results indicate that curcumin may attenuate asthma symptom by inhibiting production of cytokines related to eosinophil function and IgE synthesis, and suppressing IgE-mediated reactions and hyperreactivity.

#### *5.6.5. Licorice root (Glycyrrhiza glabra)*

Licorice root has been widely used around the world to treat cough since ancient time [247]. It contains the active compounds including glycyrrhizin, glycyrrhetinic acid, flavonoids, isoflavonoids, and chalcones [248]. Glycyrrhizin and glycyrrhetinic acid are considered to be the main active components [249] and are potent inhibitors of cortisol metabolism, due to their steroid like structures inhibiting the key steroid metabolic enzymes, delta 4-5-reductase, 11 beta-hydroxysteroid dehydrogenase and 20-hydroxysteroid dehydrogenase [250, 251]. Therefore, the benefits and side effects of steroid are both expected to be enhanced in the presence of glycyrrhetinic acid and glycyrrhizin.

Asthma in the 21st Century — Unexpected Applications of Ancient Treatments http://dx.doi.org/10.5772/56428 313

O

O

HO

OH

Glycyrrhizin

production, and modulate steroid activity. It's effect on steroid activity may be the result of

During allergic inflammation, curcumin may modulate both early and late phase responses by altering Th2 responses. In a murine latex-induced allergy model, characterized by an increased serum total IgE and latex specific IgG1, elevated peripheral blood eosinophils count, and enhanced lung tissue IL-4, IL-5 and IL-13, intragastric curcumin administration reduces lung inflammation. Protein expression of costimulatory molecules CD80, CD86, and OX40- Ligand, and RNA expression of MMP-9, ornithine aminotransferase (OAT), and thymic stromal lymphopoietin (TSLP) in antigen-presenting cells are all decreased. These results suggest that curcumin may disrupt antigen presentation, so that has potential therapeutic

Curcumin has been shown to have anti-asthmatic effects in both *in vivo* and *in vitro* studies. In OVA-induced asthma model in guinea pigs, curcumin treatment during OVA sensitization or following antigen challenge shows significant protective effects through attenuation of bronchial constriction and hyperreactivity [286]. This indicates curcumin has both preventive and therapeutic effects on asthma. In another study in an OVA-induced murine asthma model, curcumin's anti-asthmatic function is attributed to the suppression of iNOS and subsequent NO production, inhibition of inflammatory cytokine synthesis and downregulation of eosinophil recruitment to airway [91]. *In vitro*, curcumin supplementation inhibits IgE/antigen activation of mast cells through the principal activation pathway mediated by FcεRI directly inhibiting Syk kinase phosphorylation, which is critical for the propagation of signaling cascade. Subsequently, the phosphorylation of MAP kinases including p38, ERK 1/2 and JNK are supressed, which are crucial for gene transcription and production of proinflammatory cytokines [287]. In addition, curcumin inhibits HDM-induced lymphocyte proliferation and production of IL-2, IL-4, IL-5, and GM-CSF by lymphocytes from asthma patients [246]. These results indicate that curcumin may attenuate asthma symptom by inhibiting production of cytokines related to eosinophil function and IgE synthesis, and suppressing IgE-mediated

Licorice root has been widely used around the world to treat cough since ancient time [247]. It contains the active compounds including glycyrrhizin, glycyrrhetinic acid, flavonoids, isoflavonoids, and chalcones [248]. Glycyrrhizin and glycyrrhetinic acid are considered to be the main active components [249] and are potent inhibitors of cortisol metabolism, due to their steroid like structures inhibiting the key steroid metabolic enzymes, delta 4-5-reductase, 11 beta-hydroxysteroid dehydrogenase and 20-hydroxysteroid dehydrogenase [250, 251]. Therefore, the benefits and side effects of steroid are both expected to be enhanced in the

inhibition of NF-κB through blocking IKK activity [281-284].

312 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

value on allergen triggered airway inflammation [285].

reactions and hyperreactivity.

*5.6.5. Licorice root (Glycyrrhiza glabra)*

presence of glycyrrhetinic acid and glycyrrhizin.

Liquiritige

Glycyrrhetinic acid

The anti-inflammatory effect of glycyrrhizin during virus infection has been well documented [288-290] and may alleviate allergic inflammation as well. In a contact skin hypersensitivity mouse model, glycyrrhizin and its metabolite 18 β-glycyrrhetinic acid-3-O-β-D-glucuronide show protective effects in terms of reduced passive cutaneous anaphylaxis and inflammation, with glycyrrhizin being more potent than 18 β-glycyrrhetinic acid-3-O-β-D-glucuronide [291]. In an OVA-induced murine asthma model, glycyrrhizin provided orally alleviates airway constriction and hyperreactivity, pulmonary inflammation. In BAL, IFNγ level is increased, while IL-4, IL-5 levels and eosinophil count are decreased. It also reduces OVA-specific IgE levels and upregulates total IgG2a in serum as well [292]. These results indicate that glycyrrhizin interfere the production of IgE by decreasing the IgE-stimulating cytokines.

The effects of glycyrrhetinic acid and liquiritigenin (a flavonoid of licorice root) on asthma have been tested both *in vivo* and *in vitro. In vitro*, glycyrrhetinic acid and liquiritigenin inhibits β-hexosaminidase release from RBL-2H3 cells induced by IgE/DNP, and from rat peritoneal mast cells challenged with c48/80. *In vivo*, they can suppress c48/80 induced passive cutaneous anaphylactic reaction in mice. In OVA-induced murine asthma model, glycyrrhetinic acid but not liquiritigenin reduces the level of IgE in serum [293]. Flavonoids extracted from licorice root quench LPS-induced pulmonary inflammation by inhibiting the recruitment of neutro‐ phils, macrophages and lymphocytes in BALF, and suppressing the mRNA expression of TNF and IL-1β in LPS-challenged lung tissue in mice [238]. The reported side effects of licorice root includes headache, hypertension, hypokalemia, premature birth, muscle weakness, and increase body weight, which were attributed to its function on inhibiting the steroid metabo‐ lism [294].

#### *5.6.6. Modified Mai-Men-Dong-Tang*

Mai-Men-Dong-Tang is an old Chinese herb formula commonly used for treating lung diseases, which contains Ophiopogon, Ginseng, Pinellia, Licorice, Jujube, and Oryza [260]. It is reported to increase the cough threshold to inhaled capsaicin in asthmatic patients. Also, the eosinophil count in peripheral blood, sputum eosinophil ratio, and serum eosinophil cationic protein level are significantly decreased, especially in patients with severe airway inflamma‐ tion [261], which suggests that Mai-Men-Dong-Tang may alleviate asthma-related cough by inhibiting eosinophil function.

Modified Mai-Men-Dong-Tang (mMMDT) contains five herbs, Ophiopogon, American ginseng, Pinellia, Licorice root, and Lantern tridax [262]. The efficacy and safety of this formula to persistent, mild to moderate asthma has been evaluated in a double-blind, randomized clinical study of 100 patients with mild to moderate asthma. After 4 months, improvements in FEV1 and symptom scores has been reported in mMMDT treatment groups with decreased serum IgE and no drug-related adverse effects seen in terms of blood test, and liver, kidney functions [295]. Modified Mai-Men-Dong-Tang is a potential effective herb formula in treatment of childhood asthma for long time use. However, recommendation cannot be made because of small sample size used in the study.

#### *5.6.7. Ding-Chuan-Tang*

Ding-Chuan-Tang (DCT) is a traditional Chinese herb formula used for the treatment of cough, wheezing, and chest tightness, developed about four hundred years ago during the Ming dynasty. This formula contains nine herbs including *Radix glycyrrhizae, Tuber pinellia, Gingko bilboae, Herba ephedrae, Flos tussilaginis farfarae, Cortex mori albae radicis, Fructus perilla frutescens, Semen pruni armeniacae, Radix scutellariae baicalensis* [263]. In OVA-induced pig asthma model, DCT given orally to animals 30 min before antigen challenge inhibits the antigen induced immediate asthmatic responses. If it is given together with sensitization, immediate and late asthmatic responses are all suppressed. In addition, DCT relaxes trachea contracted with carbachol. The effects are attributed to decreased eosinophil infiltration to airway [263].

Randomized double-blind, placebo-controlled study to assess the effect of DCT on airway hyperreactivity in children with mild to moderate persistent asthma has shown that the FEV1 is significantly increased in DCT group (196%, p=0.034), but not in placebo control group. Compared to placebo control group, total clinical/medication score shows improvement in the DCT group (p=0.004). No side effects have been reported [296]. These results suggest that DCT might be effective in treating asthma in children. Larger sample size and wider population are required in further investigations.

#### *5.6.8. STA-1 and STA-2*

not liquiritigenin reduces the level of IgE in serum [293]. Flavonoids extracted from licorice root quench LPS-induced pulmonary inflammation by inhibiting the recruitment of neutro‐ phils, macrophages and lymphocytes in BALF, and suppressing the mRNA expression of TNF and IL-1β in LPS-challenged lung tissue in mice [238]. The reported side effects of licorice root includes headache, hypertension, hypokalemia, premature birth, muscle weakness, and increase body weight, which were attributed to its function on inhibiting the steroid metabo‐

314 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

Mai-Men-Dong-Tang is an old Chinese herb formula commonly used for treating lung diseases, which contains Ophiopogon, Ginseng, Pinellia, Licorice, Jujube, and Oryza [260]. It is reported to increase the cough threshold to inhaled capsaicin in asthmatic patients. Also, the eosinophil count in peripheral blood, sputum eosinophil ratio, and serum eosinophil cationic protein level are significantly decreased, especially in patients with severe airway inflamma‐ tion [261], which suggests that Mai-Men-Dong-Tang may alleviate asthma-related cough by

Modified Mai-Men-Dong-Tang (mMMDT) contains five herbs, Ophiopogon, American ginseng, Pinellia, Licorice root, and Lantern tridax [262]. The efficacy and safety of this formula to persistent, mild to moderate asthma has been evaluated in a double-blind, randomized clinical study of 100 patients with mild to moderate asthma. After 4 months, improvements in FEV1 and symptom scores has been reported in mMMDT treatment groups with decreased serum IgE and no drug-related adverse effects seen in terms of blood test, and liver, kidney functions [295]. Modified Mai-Men-Dong-Tang is a potential effective herb formula in treatment of childhood asthma for long time use. However, recommendation cannot be made

Ding-Chuan-Tang (DCT) is a traditional Chinese herb formula used for the treatment of cough, wheezing, and chest tightness, developed about four hundred years ago during the Ming dynasty. This formula contains nine herbs including *Radix glycyrrhizae, Tuber pinellia, Gingko bilboae, Herba ephedrae, Flos tussilaginis farfarae, Cortex mori albae radicis, Fructus perilla frutescens, Semen pruni armeniacae, Radix scutellariae baicalensis* [263]. In OVA-induced pig asthma model, DCT given orally to animals 30 min before antigen challenge inhibits the antigen induced immediate asthmatic responses. If it is given together with sensitization, immediate and late asthmatic responses are all suppressed. In addition, DCT relaxes trachea contracted with carbachol. The effects are attributed to decreased eosinophil infiltration to airway [263].

Randomized double-blind, placebo-controlled study to assess the effect of DCT on airway hyperreactivity in children with mild to moderate persistent asthma has shown that the FEV1 is significantly increased in DCT group (196%, p=0.034), but not in placebo control group. Compared to placebo control group, total clinical/medication score shows improvement in the DCT group (p=0.004). No side effects have been reported [296]. These results suggest that DCT

lism [294].

*5.6.6. Modified Mai-Men-Dong-Tang*

inhibiting eosinophil function.

*5.6.7. Ding-Chuan-Tang*

because of small sample size used in the study.

STA is a combination of mMMDT and another Chinese herb formula Liu-Wei-Di-Huang-Wan (LWDHW), which is also used by Chinese as an anti-cough agent. LWDHW contains six herbs including *Rehmannia* root, *Alisma* rhizome, *Dioscorea* rhizome, *Poria, Hoelen, Moutan* root bark, *Shanzhu yu*. The formula for STA-1 and 2 are the same while the only difference being in the preparation of LWDHW is different [265]. In a mouse asthma model induced by intraperito‐ neally administrated dermatophagoides pteronyssinus group 5 allergen (Der p 5), oral STA-1 treatment during sensitization suppresses Der p 5-specific IgE production from animals in response to inhaled Der p 5 challenge. In addition, eosinophil and neutrophil airway infiltra‐ tion, and airway hyperreactivity are all significantly reduced in STA-1 group compared to control animals [266]. The efficacy and side effects of STA-1 and STA-2 on childhood asthma treatment have been evaluated in a randomized, double-blind, placebo-controlled study. The herbs and placebo provided to pediatric patients with mild to moderate asthma reduces symptom scores, serum steroid concentration, total IgE, and allergen-specific IgE levels and improves FEV1 in the STA-1 group. STA-2 does not show protective effects. No severe side effects were reported [297]. These results indicate that STA-1 might be a valuable formula for childhood asthma, especially subjects induced by dust mite antigen. However, there is not enough evidence to draw a concrete conclusion. It is worthwhile to evaluate their potential use as immunotherapy as well.

#### *5.6.9. Anti-Asthma Herbal Medicine Intervention (ASHMI)*

ASHMI is a relatively new formula developed by a group of Chinese researchers and physi‐ cians, which is an extract from three herbs: *Radix glycyrrhizaen prednisone, Radix sophorae flavescentis*, and *Ganoderma* [267]. In OVA-induced asthma, oral ASHMI treatment before and during OVA sensitization and challenge reduces AHR represented by time-integrated change in peak airway pressure. Eosinophil infiltration in BALF, lung inflammation, OVA-specific IgE production, and level of IL-4, IL-5, and IL-13 in lung and splenocyte cultures are significantly lower in ASHMI treated mice, whereas IFN-γ production is increased [267, 268]. A 6-week treatment of ASHMI beginning 24 hr after the first OVA challenge in mice reduces early phase response by decreasing histamine, leukotriene C, and OVA-specific IgE levels, and suppresses late phase responses by decreasing eosinophil count and Th2 cytokines in BALF. In addition, it relieves contraction of murine tracheal rings by increasing the production of PGI2 [269]. These results suggest that ASHMI inhibits asthmatic inflammation and airway muscle contraction, primarily by inhibiting Th2 cell function and might be suitable for treating antigen-induced asthma in both young and old subjects.

In clinical trial, ASHMI has been shown to improve lung function indicated by increased FEV1 and peak expiratory flow. Clinical symptom scores, use of β2-bronchodilators, serum IgE level, serum IL-5, IL-13 concentrations are all reduced, and some effects are even better than prednisone. During the study no adverse effect were recorded [298]. These results indicate the effectiveness of ASHMI on treating asthma in both young and old adult patients. More adequately powered investigations are needed to evaluate ASHMI's effect on asthma.

#### **5.7. n-3 polyunsaturated fatty acids**

PUFA are a group of fatty acids with more than two carbon-carbon double bonds. There are three types of PUFA, n-3, n-6 and n-9, with their names based on the position of first double band from methyl end in their chemical structures. Currently, many studies have focused on n-3 and n-6 PUFA because EPA (20:4 n-3), Dihomo-γ-Linolenic acid (DGLA, 20:3 n-6) and Arachidonic acid (AA, 20:4 n-6) in cell membrane can be metabolized and become eicosanoid precursors, which are important modulatory autocrine molecules. Eicosanoids include prostaglandins, leukotrienes, thromboxanes, resolvins, lipoxins, are signal molecules that exert complex effects on health. They can modulate inflammation, fever, blood pressure, the immune system, etc. Eicosanoids can be made by oxidation of twenty carbon n-3 (EPA) and n-6 (DGLA, AA) PUFA. Eicosanoids from AA are proinflammatory, while those from EPA and DGLA are less so. There is competition between n-3 PUFA and n-6 PUFA in oxidation in terms of cyclooxygenase and lipoxygenase, which are critical enzymes for eicosanoid gener‐ ation. AA is the predominant n-6 PUFA in body. In general, n-3 and n-6 are hypothesized to be beneficial and detrimental respectively [299, 300]. Fish, fish oil, krill, mussel and seal oil are natural sources of n-3 PUFA.

The major n-3 PUFA are listed in Table 12. In mammals, including humans, n-3 PUFA cannot be synthesized *de novo*. Therefore they must be absorbed through the diet or produced from α-Linolenic acid (ALA), which is an essential fatty acid. Among them, the health beneficial effects of EPA and DHA (22:6 n-3) are well documented in a broad range of health and disease conditions. The consumption of EPA and DHA are associated with lower risk of cancer, hyperlipidemia, and cardiovascular disease, high blood pressure, and neurodegenerative diseases [301-304]. Their regulating function on immune system was also well known and are involved in activation of immune cells like of T cells, B cells, mast cells and basophils [305, 306].

In recent decade, the relationship between n-3 PUFA and inflammatory diseases has been investigated in many studies. In a study conducted in rheumatoid arthritis patients, significant improvement in symptoms have been reported after 3 month fish oil supplementation in terms of tender joint count and duration of morning stiffness [307]. Besides reduction in the produc‐ tion of proinflammatory eicosanoids by competition with n-6 PUFA, n-3 PUFA has been found to be effective in inhibiting the synthesis of proinflammatory cytokines. In *fat-1* transgenic mice, which have a much lower n-6:n-3 PUFA in tissues because they are genetically modified to possess the ability to convert n-6 PUFA to n-3 PUFA, serum proinflammatory cytokines, including TNF, IL-1β, and IL-6 are lower. [280]. DHA and ALA also reduce the mRNA expression of IL-1β, IL-6 in a cerulein-induced pancreatitis model. They inhibit the activation of AP-1, suppress DNA fragmentation and decrease mRNA expression of apoptotic genes including p53, Bax and apoptosis-inducing factor in hydrogen peroxide-treated pancreatic acinar cells [308]. A randomized, double-blind human study has confirmed their suppressing effect on production of proinflammatory cytokines [309]. It has been shown that n-3 fatty acids


**Table 12.** The common name, lipid name and chemical name of major n-3 PUFA

effectiveness of ASHMI on treating asthma in both young and old adult patients. More adequately powered investigations are needed to evaluate ASHMI's effect on asthma.

PUFA are a group of fatty acids with more than two carbon-carbon double bonds. There are three types of PUFA, n-3, n-6 and n-9, with their names based on the position of first double band from methyl end in their chemical structures. Currently, many studies have focused on n-3 and n-6 PUFA because EPA (20:4 n-3), Dihomo-γ-Linolenic acid (DGLA, 20:3 n-6) and Arachidonic acid (AA, 20:4 n-6) in cell membrane can be metabolized and become eicosanoid precursors, which are important modulatory autocrine molecules. Eicosanoids include prostaglandins, leukotrienes, thromboxanes, resolvins, lipoxins, are signal molecules that exert complex effects on health. They can modulate inflammation, fever, blood pressure, the immune system, etc. Eicosanoids can be made by oxidation of twenty carbon n-3 (EPA) and n-6 (DGLA, AA) PUFA. Eicosanoids from AA are proinflammatory, while those from EPA and DGLA are less so. There is competition between n-3 PUFA and n-6 PUFA in oxidation in terms of cyclooxygenase and lipoxygenase, which are critical enzymes for eicosanoid gener‐ ation. AA is the predominant n-6 PUFA in body. In general, n-3 and n-6 are hypothesized to be beneficial and detrimental respectively [299, 300]. Fish, fish oil, krill, mussel and seal oil are

The major n-3 PUFA are listed in Table 12. In mammals, including humans, n-3 PUFA cannot be synthesized *de novo*. Therefore they must be absorbed through the diet or produced from α-Linolenic acid (ALA), which is an essential fatty acid. Among them, the health beneficial effects of EPA and DHA (22:6 n-3) are well documented in a broad range of health and disease conditions. The consumption of EPA and DHA are associated with lower risk of cancer, hyperlipidemia, and cardiovascular disease, high blood pressure, and neurodegenerative diseases [301-304]. Their regulating function on immune system was also well known and are involved in activation of immune cells like of T cells, B cells, mast cells and basophils [305, 306].

In recent decade, the relationship between n-3 PUFA and inflammatory diseases has been investigated in many studies. In a study conducted in rheumatoid arthritis patients, significant improvement in symptoms have been reported after 3 month fish oil supplementation in terms of tender joint count and duration of morning stiffness [307]. Besides reduction in the produc‐ tion of proinflammatory eicosanoids by competition with n-6 PUFA, n-3 PUFA has been found to be effective in inhibiting the synthesis of proinflammatory cytokines. In *fat-1* transgenic mice, which have a much lower n-6:n-3 PUFA in tissues because they are genetically modified to possess the ability to convert n-6 PUFA to n-3 PUFA, serum proinflammatory cytokines, including TNF, IL-1β, and IL-6 are lower. [280]. DHA and ALA also reduce the mRNA expression of IL-1β, IL-6 in a cerulein-induced pancreatitis model. They inhibit the activation of AP-1, suppress DNA fragmentation and decrease mRNA expression of apoptotic genes including p53, Bax and apoptosis-inducing factor in hydrogen peroxide-treated pancreatic acinar cells [308]. A randomized, double-blind human study has confirmed their suppressing effect on production of proinflammatory cytokines [309]. It has been shown that n-3 fatty acids

**5.7. n-3 polyunsaturated fatty acids**

316 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

natural sources of n-3 PUFA.

can alleviate inflammatory process by modulating cell signalling pathways in immune cells, such as T cell receptor pathway and cytokine receptor pathways. [310-312]

There have been a number of clinical studies that have shown n-3 PUFA's potentially protective effects on asthma, especially on childhood patients. There is a positive association between the n-6:n-3 PUFA in diet and risk for asthma [313]. A randomized, double-blind, placebocontrolled 3-year study on effect of n-3 PUFA supplementation on asthma has found that high n-3 PUFA diet intervention significantly reducesd the prevalence of cough in atopic children, suggesting that n-3 PUFA may be effective in preventing the development of asthma in early childhood [314]. In a cohort study on the relations between fish/cod oil intake and asthma, results have shown that adults with low fish intake frequency (less than weekly) have increased risk to have asthma [315]. Another randomized double-blind study with 5-weeks n-3 PUFA supplementation has reported a significant decrease in exhaled NO from asthma patients challenged with mite allergen. Serum eosinophils count and ECP, and the production of CysLTs from isolated leukocyte stimulated with mite antigen are also reduced [194]. Overall, n-3 PUFA might be a promising remedy agents for allergic diseases like asthma but the mechanism remains to be elucidated.

#### **6. Conclusion**

The prevalence of asthma is becoming the mortality and morbidity pandemic of the 21st century. The cost of in quality of patient's lives and economic burden of treatment is continuing to grow at pace unmatched in our current health system. It is impossible to enter public classroom now without seeing a young sufferer of this condition and any trip to the emergency department will show how dangerous this disease can be. As the incidence and severity of the disease continues to rise, medical research is continuing to search new treatment strategies. While many treatments currently exists those reserve for the severest of conditions carry their own inherent risk which may match the severity of disease itself. It is for these reasons alone that health care professionals are now examining the traits of our ancestors in time when this epidemic was less severe to determine if their medicines and practices hold the answer for the next treatment strategy. By combining the scientific knowledge at the molecular and clinical level and the resources of past it might hold the answer to breathless pandemic of the 21st century.

#### **Acknowledgements**

The authors are thankful to Dr. Clayton Macdonald for his assiatance with the manuscript preparation. This work is supported by the National Research Council Canada. Priyanka Pundir is the recipient of Innovation PEI Graduate Student Fellowship.

#### **Author details**

Priyanka Pundir1,2, Xiaofeng Wang1,2 and Marianna Kulka3

1 National Research Council Canada, Charlottetown, PE, Canada

2 Department of Biomedical Sciences, Atlantic Veterinary College, University of Prince Ed‐ ward Island, Charlottetown, PE, Canada

3 National Research Council Canada, Edmonton, AB, Canada

### **References**

results have shown that adults with low fish intake frequency (less than weekly) have increased risk to have asthma [315]. Another randomized double-blind study with 5-weeks n-3 PUFA supplementation has reported a significant decrease in exhaled NO from asthma patients challenged with mite allergen. Serum eosinophils count and ECP, and the production of CysLTs from isolated leukocyte stimulated with mite antigen are also reduced [194]. Overall, n-3 PUFA might be a promising remedy agents for allergic diseases like asthma but the

The prevalence of asthma is becoming the mortality and morbidity pandemic of the 21st century. The cost of in quality of patient's lives and economic burden of treatment is continuing to grow at pace unmatched in our current health system. It is impossible to enter public classroom now without seeing a young sufferer of this condition and any trip to the emergency department will show how dangerous this disease can be. As the incidence and severity of the disease continues to rise, medical research is continuing to search new treatment strategies. While many treatments currently exists those reserve for the severest of conditions carry their own inherent risk which may match the severity of disease itself. It is for these reasons alone that health care professionals are now examining the traits of our ancestors in time when this epidemic was less severe to determine if their medicines and practices hold the answer for the next treatment strategy. By combining the scientific knowledge at the molecular and clinical level and the resources of past it might hold the answer to breathless pandemic of the 21st

The authors are thankful to Dr. Clayton Macdonald for his assiatance with the manuscript preparation. This work is supported by the National Research Council Canada. Priyanka

2 Department of Biomedical Sciences, Atlantic Veterinary College, University of Prince Ed‐

Pundir is the recipient of Innovation PEI Graduate Student Fellowship.

Priyanka Pundir1,2, Xiaofeng Wang1,2 and Marianna Kulka3

ward Island, Charlottetown, PE, Canada

1 National Research Council Canada, Charlottetown, PE, Canada

3 National Research Council Canada, Edmonton, AB, Canada

mechanism remains to be elucidated.

318 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

**6. Conclusion**

century.

**Acknowledgements**

**Author details**


[14] Fogarty A, Lewis S, Weiss S, Britton J. Dietary vitamin E, IgE concentrations, and ato‐

[15] Butland BK, Strachan DP, Anderson HR. Fresh fruit intake and asthma symptoms in young British adults: confounding or effect modification by smoking? Eur Respir J.

[16] Miedema I, Feskens EJ, Heederik D, Kromhout D. Dietary determinants of long-term incidence of chronic nonspecific lung diseases. The Zutphen Study. Am J Epidemiol.

[17] Carey IM, Strachan DP, Cook DG. Effects of changes in fresh fruit consumption on ventilatory function in healthy British adults. Am J Respir Crit Care Med.

[18] Shaheen SO, Sterne JA, Thompson RL, Songhurst CE, Margetts BM, Burney PG. Diet‐ ary antioxidants and asthma in adults: population-based case-control study. Am J

[19] Dow L, Tracey M, Villar A, Coggon D, Margetts BM, Campbell MJ, et al. Does diet‐ ary intake of vitamins C and E influence lung function in older people? Am J Respir

[20] Morabia A, Sorenson A, Kumanyika SK, Abbey H, Cohen BH, Chee E. Vitamin A, cigarette smoking, and airway obstruction. The American review of respiratory dis‐

[21] La Vecchia C, Decarli A, Pagano R. Vegetable consumption and risk of chronic dis‐

[22] Ellwood P, Asher MI, Bjorksten B, Burr M, Pearce N, Robertson CF. Diet and asthma, allergic rhinoconjunctivitis and atopic eczema symptom prevalence: an ecological analysis of the International Study of Asthma and Allergies in Childhood (ISAAC) data. ISAAC Phase One Study Group. Eur Respir J. 2001;17(3):436-43. Epub

[23] Arts IC, Hollman PC. Polyphenols and disease risk in epidemiologic studies. The American journal of clinical nutrition. 2005;81(1 Suppl):317S-25S. Epub 2005/01/11.

[24] Barrett NA, Austen KF. Innate cells and T helper 2 cell immunity in airway inflam‐

[25] Halwani R, Al-Muhsen S, Hamid Q. Airway remodeling in asthma. Curr Opin Phar‐

[26] Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature.

[27] Holt PG. Antigen presentation in the lung. Am J Respir Crit Care Med. 2000;162(4 Pt

Respir Crit Care Med. 2001;164(10 Pt 1):1823-8. Epub 2001/12/06.

Crit Care Med. 1996;154(5):1401-4. Epub 1996/11/01.

ease. Epidemiology. 1998;9(2):208-10. Epub 1998/03/21.

ease. 1989;140(5):1312-6. Epub 1989/11/01.

mation. Immunity. 2009;31(3):425-37.

2008;454(7203):445-54. Epub 2008/07/25.

2001/06/19.

macol.10(3):236-45.

2):S151-6.

py. Lancet. 2000;356(9241):1573-4. Epub 2000/11/15.

320 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

1999;13(4):744-50. Epub 1999/06/11.

1993;138(1):37-45. Epub 1993/07/01.

1998;158(3):728-33. Epub 1998/09/10.


[55] Rosenwasser LJ, Rothenberg ME. IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome. J Allergy Clin Immunol.125(6):1245-6.

[43] Fahy JV, Kim KW, Liu J, Boushey HA. Prominent neutrophilic inflammation in spu‐ tum from subjects with asthma exacerbation. J Allergy Clin Immunol. 1995;95(4):

[44] Hamzaoui A, Hamzaoui K, Salah H, Chabbou A. Lymphocytes apoptosis in patients with acute exacerbation of asthma. Mediators of inflammation. 1999;8(4-5):237-43.

[45] Robinson D, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR. Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic

[46] Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. The New England journal of medicine. 1997;337(1):8-14. Epub 1997/07/03.

[47] van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of frac‐ tures. Journal of bone and mineral research : the official journal of the American Soci‐

[48] Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Longterm inhaled corticosteroids in preschool children at high risk for asthma. The New

[49] Lou HQ, Ying YF, Hu Y. [CRTH2 antagonist ameliorates airway inflammation in rats

[50] Lukacs NW, Berlin AA, Franz-Bacon K, Sasik R, Sprague LJ, Ly TW, et al. CRTH2 an‐ tagonism significantly ameliorates airway hyperreactivity and downregulates in‐ flammation-induced genes in a mouse model of airway inflammation. Am J Physiol

[51] Hicks A, Goodnow R, Jr., Cavallo G, Tannu SA, Ventre JD, Lavelle D, et al. Effects of LTB4 receptor antagonism on pulmonary inflammation in rodents and non-human

[52] Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, Nagai H. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from hu‐

[53] Siegle JS, Hansbro N, Dong C, Angkasekwinai P, Foster PS, Kumar RK. Blocking in‐ duction of T helper type 2 responses prevents development of disease in a model of

[54] Caramori G, Groneberg D, Ito K, Casolari P, Adcock IM, Papi A. New drugs target‐ ing Th2 lymphocytes in asthma. J Occup Med Toxicol. 2008;3 Suppl 1:S6. Epub

asthma. J Allergy Clin Immunol. 1993;92(2):313-24. Epub 1993/08/01.

ety for Bone and Mineral Research. 2001;16(3):581-8. Epub 2001/03/30.

England journal of medicine. 2006;354(19):1985-97. Epub 2006/05/12.

with asthma]. Zhejiang Da Xue Xue Bao Yi Xue Ban.39(1):64-70.

primates. Prostaglandins Other Lipid Mediat.92(1-4):33-43.

man cultured mast cells. Clin Exp Allergy. 2000;30(4):501-8.

Lung Cell Mol Physiol. 2008;295(5):L767-79.

childhood asthma. Clin Exp Immunol.

2008/03/05.

843-52. Epub 1995/04/01.

322 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

Epub 2000/03/07.


NF-kappaB translocation in LPS stimulated RAW 264.7 cells. Eur J Pharmacol. 660(2-3):454-9.


[79] Bodet C, La VD, Epifano F, Grenier D. Naringenin has anti-inflammatory properties in macrophage and ex vivo human whole-blood models. J Periodontal Res. 2008;43(4):400-7.

NF-kappaB translocation in LPS stimulated RAW 264.7 cells. Eur J Pharmacol.

[68] Kang OH, Jang HJ, Chae HS, Oh YC, Choi JG, Lee YS, et al. Anti-inflammatory mech‐ anisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-kappaB and

[69] Jin M, Yang JH, Lee E, Lu Y, Kwon S, Son KH, et al. Antiasthmatic activity of luteo‐ lin-7-O-glucoside from Ailanthus altissima through the downregulation of T helper 2 cytokine expression and inhibition of prostaglandin E2 production in an ovalbumin-

[70] Kempuraj D, Tagen M, Iliopoulou BP, Clemons A, Vasiadi M, Boucher W, et al. Lu‐ teolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells. Br J Pharmacol. 2008;155(7):1076-84.

[71] Hougee S, Sanders A, Faber J, Graus YM, van den Berg WB, Garssen J, et al. De‐ creased pro-inflammatory cytokine production by LPS-stimulated PBMC upon in vi‐ tro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective

elimination of monocytes/macrophages. Biochem Pharmacol. 2005;69(2):241-8.

reactivity in ovalbumin sensitized mice. Inflamm Res. 2003;52(3):101-6.

production from RBL-2H3 cells. Bioorg Med Chem. 2002;10(10):3123-8.

[72] Das M, Ram A, Ghosh B. Luteolin alleviates bronchoconstriction and airway hyper‐

[73] Mastuda H, Morikawa T, Ueda K, Managi H, Yoshikawa M. Structural requirements of flavonoids for inhibition of antigen-Induced degranulation, TNF-alpha and IL-4

[74] Harasstani OA, Moin S, Tham CL, Liew CY, Ismail N, Rajajendram R, et al. Flavo‐ noid combinations cause synergistic inhibition of proinflammatory mediator secre‐ tion from lipopolysaccharide-induced RAW 264.7 cells. Inflamm Res.59(9):711-21.

[75] Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N, et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion lev‐ els and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol.

[76] Park HH, Lee S, Son HY, Park SB, Kim MS, Choi EJ, et al. Flavonoids inhibit hista‐ mine release and expression of proinflammatory cytokines in mast cells. Arch Pharm

[77] Iwamura C, Shinoda K, Yoshimura M, Watanabe Y, Obata A, Nakayama T. Naringe‐ nin chalcone suppresses allergic asthma by inhibiting the type-2 function of CD4 T

[78] Shi Y, Dai J, Liu H, Li RR, Sun PL, Du Q, et al. Naringenin inhibits allergen-induced airway inflammation and airway responsiveness and inhibits NF-kappaB activity in

a murine model of asthma. Can J Physiol Pharmacol. 2009;87(9):729-35.

660(2-3):454-9.

2005;145(7):934-44.

Res. 2008;31(10):1303-11.

cells. Allergol Int.59(1):67-73.

MAPK. Pharmacol Res. 2009;59(5):330-7.

324 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

induced asthma model. Biol Pharm Bull. 2009;32(9):1500-3.


[102] Kim SH, Jun CD, Suk K, Choi BJ, Lim H, Park S, et al. Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells. Toxicol Sci. 2006;91(1):123-31.

[91] Moon DO, Kim MO, Lee HJ, Choi YH, Park YM, Heo MS, et al. Curcumin attenuates ovalbumin-induced airway inflammation by regulating nitric oxide. Biochem Bio‐

[92] Wong CK, Li ML, Wang CB, Ip WK, Tian YP, Lam CW. House dust mite allergen Der p 1 elevates the release of inflammatory cytokines and expression of adhesion mole‐ cules in co-culture of human eosinophils and bronchial epithelial cells. Int Immunol.

[93] Kobayashi T, Hashimoto S, Horie T. Curcumin inhibition of Dermatophagoides fari‐ nea-induced interleukin-5 (IL-5) and granulocyte macrophage-colony stimulating factor (GM-CSF) production by lymphocytes from bronchial asthmatics. Biochem

[94] Baek OS, Kang OH, Choi YA, Choi SC, Kim TH, Nah YH, et al. Curcumin inhibits protease-activated receptor-2 and -4-mediated mast cell activation. Clin Chim Acta.

[95] Temkin V, Kantor B, Weg V, Hartman ML, Levi-Schaffer F. Tryptase activates the mi‐ togen-activated protein kinase/activator protein-1 pathway in human peripheral blood eosinophils, causing cytokine production and release. J Immunol. 2002;169(5):

[96] Bani D, Giannini L, Ciampa A, Masini E, Suzuki Y, Menegazzi M, et al. Epigallocate‐ chin-3-gallate reduces allergen-induced asthma-like reaction in sensitized guinea

[97] Shin HY, Kim SH, Jeong HJ, Kim SY, Shin TY, Um JY, et al. Epigallocatechin-3-gallate inhibits secretion of TNF-alpha, IL-6 and IL-8 through the attenuation of ERK and

[98] Syed DN, Afaq F, Kweon MH, Hadi N, Bhatia N, Spiegelman VS, et al. Green tea pol‐ yphenol EGCG suppresses cigarette smoke condensate-induced NF-kappaB activa‐

[99] Bae HB, Li M, Kim JP, Kim SJ, Jeong CW, Lee HG, et al. The effect of epigallocatechin gallate on lipopolysaccharide-induced acute lung injury in a murine model. Inflam‐

[100] Rodrigues TG, Fernandes A, Jr., Sousa JP, Bastos JK, Sforcin JM. In vitro and in vivo effects of clove on pro-inflammatory cytokines production by macrophages. Nat

[101] Adhami VM, Malik A, Zaman N, Sarfaraz S, Siddiqui IA, Syed DN, et al. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer

tion in normal human bronchial epithelial cells. Oncogene. 2007;26(5):673-82.

NF-kappaB in HMC-1 cells. Int Arch Allergy Immunol. 2007;142(4):335-44.

phys Res Commun. 2008;375(2):275-9.

326 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

2006;18(8):1327-35.

2003;338(1-2):135-41.

mation.33(2):82-91.

Prod Res. 2009;23(4):319-26.

Res. 2007;13(5):1611-9.

2662-9.

Pharmacol. 1997;54(7):819-24.

pigs. J Pharmacol Exp Ther. 2006;317(3):1002-11.


tion of bone marrow CD34 progenitor cells in an allergic mouse model. Allergy. 2008;63(9):1164-76.


man keratinocytes stimulated with the proinflammatory cytokine TNFalpha. Arch Dermatol Res. 2003;295(3):112-6.

[126] Saito N, Yamada Y, Sannohe S, Honda K, Adachi T, Kayaba H, et al. Possible in‐ volvement of C-C chemokines in functional augmentation of adhesion molecules in asthmatic patients. Lung. 2002;180(5):251-63.

tion of bone marrow CD34 progenitor cells in an allergic mouse model. Allergy.

[115] Das AM, Vaddi KG, Solomon KA, Krauthauser C, Jiang X, McIntyre KW, et al. Selec‐ tive inhibition of eosinophil influx into the lung by small molecule CC chemokine re‐ ceptor 3 antagonists in mouse models of allergic inflammation. J Pharmacol Exp

[116] Nakagami Y, Kawase Y, Yonekubo K, Nosaka E, Etori M, Takahashi S, et al. RS-1748, a novel CC chemokine receptor 4 antagonist, inhibits ovalbumin-induced airway in‐

[117] Vijayanand P, Durkin K, Hartmann G, Morjaria J, Seumois G, Staples KJ, et al. Che‐ mokine receptor 4 plays a key role in T cell recruitment into the airways of asthmatic

[118] Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M, et al. An oral‐ ly bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhib‐ its prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther.

[119] Uller L, Mathiesen JM, Alenmyr L, Korsgren M, Ulven T, Hogberg T, et al. Antago‐ nism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse

[120] Huang CH, Kuo PL, Hsu YL, Chang TT, Tseng HI, Chu YT, et al. The natural flavo‐ noid apigenin suppresses Th1- and Th2-related chemokine production by human monocyte THP-1 cells through mitogen-activated protein kinase pathways. J Med

[121] Kowalski J, Samojedny A, Paul M, Pietsz G. [Apigenin inhibits release and gene ex‐ pression of monocyte chemoattractant protein 1 (MCP-1) in J774.2 macrophages]. Wiad Lek. 2006;59(9-10):634-8. Hamujacy wplyw apigeniny na wydzielanie i ekspres‐ ji genu bialka chemotaktycznego monocytow (MCP-1) w hodowli makrofagow linii

[122] Nakajima T, Imanishi M, Yamamoto K, Cyong JC, Hirai K. Inhibitory effect of baica‐ lein, a flavonoid in Scutellaria Root, on eotaxin production by human dermal fibro‐

[123] Lee S, Kim YJ, Kwon S, Lee Y, Choi SY, Park J, et al. Inhibitory effects of flavonoids on TNF-alpha-induced IL-8 gene expression in HEK 293 cells. BMB Rep. 2009;42(5):

[124] Sohn MH, Lee KE, Kim KW, Kim ES, Park JY, Kim KE. Calcium-calmodulin mediates house dust mite-induced ERK activation and IL-8 production in human respiratory

[125] Trompezinski S, Denis A, Schmitt D, Viac J. Comparative effects of polyphenols from green tea (EGCG) and soybean (genistein) on VEGF and IL-8 release from normal hu‐

flammation in guinea pigs. Biol Pharm Bull.33(6):1067-9.

328 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

eosinophilic airway inflammation. Respir Res. 2007;8:16.

2008;63(9):1164-76.

Ther. 2006;318(1):411-7.

2003;305(1):347-52.

Food.13(2):391-8.

J774.2.

265-70.

patients. J Immunol.184(8):4568-74.

blasts. Planta Med. 2001;67(2):132-5.

epithelial cells. Respiration. 2007;74(4):447-53.


matory genes in interferon-gamma-stimulated macrophages. J Pharmacol Sci.112(4): 405-14.


[149] Ju SM, Song HY, Lee SJ, Seo WY, Sin DH, Goh AR, et al. Suppression of thymus- and activation-regulated chemokine (TARC/CCL17) production by 1,2,3,4,6-penta-O-gal‐ loyl-beta-D-glucose via blockade of NF-kappaB and STAT1 activation in the HaCaT cells. Biochem Biophys Res Commun. 2009;387(1):115-20.

matory genes in interferon-gamma-stimulated macrophages. J Pharmacol Sci.112(4):

[138] Wang J, Zhang Y, Yang C, Hou M, Wang F, Wang G, et al. [Effect of tectorigenin on MCP-1 and ICAM-1 mRNA expression in injured vascular endothelial cells]. Zhong‐

[139] Lee BS, Shim SM, Heo J, Pae HO, Seo BY, Han SY, et al. Wogonin suppresses TARC expression induced by mite antigen via heme oxygenase 1 in human keratinocytes. Suppressive effect of wogonin on mite antigen-induced TARC expression. J Derma‐

[140] Hong JY, Lee KE, Kim KW, Sohn MH, Kim KE. Chitinase induce the release of IL-8 in human airway epithelial cells, via Ca2+-dependent PKC and ERK pathways. Scand J

[141] Liao YR, Hsu JY, Chu JJ, Fu LS. Caffeic acid phenethyl ester suppresses the induction

[142] Han KH, Hong KH, Ko J, Rhee KS, Hong MK, Kim JJ, et al. Lysophosphatidylcholine up-regulates CXCR4 chemokine receptor expression in human CD4 T cells. J Leukoc

[143] Lin YT, Hsu JY, Chen CJ, Chu JJ, Fu LS. Caffeic acid phenethyl ester suppresses eo‐ taxin secretion and nuclear p-STAT6 in human lung fibroblast cells. J Microbiol Im‐

[144] Qin S, Alcorn JF, Craigo JK, Tjoeng C, Tarwater PM, Kolls JK, et al. Epigallocate‐ chin-3-gallate reduces airway inflammation in mice through binding to proinflam‐ matory chemokines and inhibiting inflammatory cell recruitment. J Immunol.186(6):

[145] Melgarejo E, Medina MA, Sanchez-Jimenez F, Urdiales JL. Epigallocatechin gallate reduces human monocyte mobility and adhesion in vitro. Br J Pharmacol.

[146] Melgarejo E, Medina MA, Sanchez-Jimenez F, Botana LM, Dominguez M, Escribano L, et al. (-)-Epigallocatechin-3-gallate interferes with mast cell adhesiveness, migra‐ tion and its potential to recruit monocytes. Cell Mol Life Sci. 2007;64(19-20):2690-701.

[147] Takano K, Nakaima K, Nitta M, Shibata F, Nakagawa H. Inhibitory effect of (-)-epi‐ gallocatechin 3-gallate, a polyphenol of green tea, on neutrophil chemotaxis in vitro

[148] Kiss AK, Filipek A, Czerwinska M, Naruszewicz M. Oenothera paradoxa defatted seeds extract and its bioactive component penta-O-galloyl-beta-D-glucose decreased production of reactive oxygen species and inhibited release of leukotriene B4, inter‐ leukin-8, elastase, and myeloperoxidase in human neutrophils. J Agric Food Chem.

and in vivo. J Agric Food Chem. 2004;52(14):4571-6.

of eotaxin in human lung fibroblast cells. J Asthma.47(3):233-7.

405-14.

guo Zhong Yao Za Zhi.35(15):2001-3.

330 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

tol Sci. 2007;46(1):31-40.

Immunol.72(1):15-21.

Biol. 2004;76(1):195-202.

munol Infect.

3693-700.

2009;158(7):1705-12.

58(18):9960-6.


inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells. J Pharmacol Exp Ther. 2006;317(3):989-1001. Epub 2006/03/10.

[174] Ziegelbauer K, Gantner F, Lukacs NW, Berlin A, Fuchikami K, Niki T, et al. A selec‐ tive novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) pre‐ vents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol. 2005;145(2):178-92. Epub 2005/03/09.

[161] Matsuda H, Tewtrakul S, Morikawa T, Nakamura A, Yoshikawa M. Anti-allergic principles from Thai zedoary: structural requirements of curcuminoids for inhibition of degranulation and effect on the release of TNF-alpha and IL-4 in RBL-2H3 cells.

[162] Nishikawa H, Wakano K, Kitani S. Inhibition of NADPH oxidase subunits transloca‐ tion by tea catechin EGCG in mast cell. Biochem Biophys Res Commun. 2007;362(2):

[163] Kim Y, Kim K, Lee H, Han S, Lee YS, Choe J, et al. Celastrol binds to ERK and inhib‐ its FcepsilonRI signaling to exert an anti-allergic effect. Eur J Pharmacol.

[164] Kim TJ, Nam KW, Kim B, Lee SJ, Oh KB, Kim KH, et al. Inhibitory Effects of Costu‐ nolide Isolated from Laurus nobilis on IgE-induced Degranulation of Mast Cell-like

[165] Duan W, Chan JH, McKay K, Crosby JR, Choo HH, Leung BP, et al. Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in

[166] Hirota R, Roger NN, Nakamura H, Song HS, Sawamura M, Suganuma N. Anti-in‐ flammatory effects of limonene from yuzu (Citrus junos Tanaka) essential oil on eosi‐

[167] Kannaiyan R, Shanmugam MK, Sethi G. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and

[168] Kim DY, Park JW, Jeoung D, Ro JY. Celastrol suppresses allergen-induced airway in‐ flammation in a mouse allergic asthma model. Eur J Pharmacol. 2009;612(1-3):98-105.

[169] Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma.

[170] Kim JY, Kwon EY, Lee YS, Kim WB, Ro JY. Eupatilin blocks mediator release via ty‐ rosine kinase inhibition in activated guinea pig lung mast cells. Journal of toxicology

[171] Kampe M, Lampinen M, Stolt I, Janson C, Stalenheim G, Carlson M. PI3-kinase regu‐ lates eosinophil and neutrophil degranulation in patients with allergic rhinitis and al‐ lergic asthma irrespective of allergen challenge model. Inflammation.35(1):230-9. [172] Yu T, Lee YJ, Jang HJ, Kim AR, Hong S, Kim TW, et al. Anti-inflammatory activity of Sorbus commixta water extract and its molecular inhibitory mechanism. J Ethnophar‐

[173] Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, Dasilva J, et al. A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated

and environmental health Part A. 2005;68(23-24):2063-80. Epub 2005/12/06.

RBL-2H3 Cells and the Growth of Y16 pro-B Cells. Phytother Res.

mice. Am J Respir Crit Care Med. 2005;171(6):571-8. Epub 2004/11/24.

Bioorg Med Chem. 2004;12(22):5891-8.

332 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

504-9.

2009;612(1-3):131-42.

nophils. J Food Sci.75(3):H87-92.

cancer. Cancer Lett.303(1):9-20.

Lancet. 2008;372(9643):1073-87. Epub 2008/09/23.

Epub 2009/04/10.

macol.134(2):493-500.


Chinese herb formulation 'San-Ao decoction'. Molecules. 2009;14(10):3942-51. Epub 2009/11/20.


[197] Al Senaidy AM. Serum vitamin A and beta-carotene levels in children with asthma. J Asthma. 2009;46(7):699-702.

Chinese herb formulation 'San-Ao decoction'. Molecules. 2009;14(10):3942-51. Epub

[186] Culpitt SV, Rogers DF, Fenwick PS, Shah P, De Matos C, Russell RE, et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in

[187] Lee NH, Lee MY, Lee JA, Jung DY, Seo CS, Kim JH, et al. Anti-asthmatic effect of Sanguisorba officinalis L. and potential role of heme oxygenase-1 in an ovalbumininduced murine asthma model. Int J Mol Med. 2010;26(2):201-8. Epub 2010/07/03. [188] Choi JH, Hwang YP, Lee HS, Jeong HG. Inhibitory effect of Platycodi Radix on oval‐ bumin-induced airway inflammation in a murine model of asthma. Food Chem Toxi‐

[189] Lee MY, Seo CS, Ha H, Jung D, Lee H, Lee NH, et al. Protective effects of Ulmus da‐ vidiana var. japonica against OVA-induced murine asthma model via upregulation

[190] Lee MY, Lee NH, Seo CS, Lee JA, Jung D, Kim JH, et al. Alpinia katsumadai seed ex‐ tract attenuate oxidative stress and asthmatic activity in a mouse model of allergic

[191] Lee JH, Zhou HY, Cho SY, Kim YS, Lee YS, Jeong CS. Anti-inflammatory mecha‐ nisms of apigenin: inhibition of cyclooxygenase-2 expression, adhesion of monocytes to human umbilical vein endothelial cells, and expression of cellular adhesion mole‐

[192] Lin HY, Juan SH, Shen SC, Hsu FL, Chen YC. Inhibition of lipopolysaccharide-in‐ duced nitric oxide production by flavonoids in RAW264.7 macrophages involves

[193] Qiao S, Li W, Tsubouchi R, Haneda M, Murakami K, Takeuchi F, et al. Rosmarinic acid inhibits the formation of reactive oxygen and nitrogen species in RAW264.7

[194] Schubert R, Kitz R, Beermann C, Rose MA, Lieb A, Sommerer PC, et al. Effect of n-3 polyunsaturated fatty acids in asthma after low-dose allergen challenge. Int Arch Al‐

[195] Riedl MA, Nel AE. Importance of oxidative stress in the pathogenesis and treatment of asthma. Current opinion in allergy and clinical immunology. 2008;8(1):49-56. Epub

[196] Allen S, Britton JR, Leonardi-Bee JA. Association between antioxidant vitamins and asthma outcome measures: systematic review and meta-analysis. Thorax. 2009;64(7):

of heme oxygenase-1. J Ethnopharmacol. 2010;130(1):61-9. Epub 2010/04/28.

asthma. Food Chem Toxicol. 2010;48(6):1746-52. Epub 2010/04/14.

heme oxygenase-1. Biochem Pharmacol. 2003;66(9):1821-32.

macrophages. Free Radic Res. 2005;39(9):995-1003.

lergy Immunol. 2009;148(4):321-9.

2008/01/12.

610-9.

COPD. Thorax. 2003;58(11):942-6. Epub 2003/10/31.

334 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

col. 2009;47(6):1272-9. Epub 2009/03/07.

cules. Arch Pharm Res. 2007;30(10):1318-27.

2009/11/20.


[223] Suchankova J, Voprsalova M, Kottova M, Semecky V, Visnovsky P. Effects of oral al‐ pha-tocopherol on lung response in rat model of allergic asthma. Respirology. 2006;11(4):414-21.

[211] Kaur B, Rowe BH, Arnold E. Vitamin C supplementation for asthma. Cochrane Data‐

[212] Guaiquil VH, Vera JC, Golde DW. Mechanism of vitamin C inhibition of cell death induced by oxidative stress in glutathione-depleted HL-60 cells. J Biol Chem.

[213] Benkoussa M, Brand C, Delmotte MH, Formstecher P, Lefebvre P. Retinoic acid re‐ ceptors inhibit AP1 activation by regulating extracellular signal-regulated kinase and CBP recruitment to an AP1-responsive promoter. Molecular and cellular biology.

[214] Meves A, Stock SN, Beyerle A, Pittelkow MR, Peus D. Vitamin C derivative ascorbyl palmitate promotes ultraviolet-B-induced lipid peroxidation and cytotoxicity in kera‐ tinocytes. The Journal of investigative dermatology. 2002;119(5):1103-8. Epub

[215] Bakkeheim E, Mowinckel P, Carlsen KH, Burney P, Carlsen KC. Altered oxidative state in schoolchildren with asthma and allergic rhinitis. Pediatr Allergy Immunol.

[216] Turner SW, Campbell D, Smith N, Craig LC, McNeill G, Forbes SH, et al. Associa‐ tions between fetal size, maternal {alpha}-tocopherol and childhood asthma. Thorax.

[217] de Luis DA, Armentia A, Aller R, Asensio A, Sedano E, Izaola O, et al. Dietary intake in patients with asthma: a case control study. Nutrition. 2005;21(3):320-4.

[218] Misso NL, Brooks-Wildhaber J, Ray S, Vally H, Thompson PJ. Plasma concentrations of dietary and nondietary antioxidants are low in severe asthma. Eur Respir J.

[219] Pearson PJ, Lewis SA, Britton J, Fogarty A. Vitamin E supplements in asthma: a par‐ allel group randomised placebo controlled trial. Thorax. 2004;59(8):652-6.

[220] Mabalirajan U, Aich J, Leishangthem GD, Sharma SK, Dinda AK, Ghosh B. Effects of vitamin E on mitochondrial dysfunction and asthma features in an experimental al‐

[221] Lim Y, Vasu VT, Valacchi G, Leonard S, Aung HH, Schock BC, et al. Severe vitamin E deficiency modulates airway allergic inflammatory responses in the murine asthma

[222] Chhabra SK, Yasir A, Chaudhry K, Shah B. Effect of ozone on response to ovalbumin & its modulation by vitamins C & E in sensitized guinea pigs. Indian J Med Res.

lergic murine model. J Appl Physiol. 2009;107(4):1285-92.

model. Free Radic Res. 2008;42(4):387-96.

base Syst Rev. 2009(1):CD000993.

2001;276(44):40955-61. Epub 2001/09/05.

336 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

2002;22(13):4522-34. Epub 2002/06/08.

2002/11/26.

22(2):178-85.

65(5):391-7.

2005;26(2):257-64.

132:87-93.


duced phosphorylation of retinoblastoma protein and checkpoint kinase 1. Br J Phar‐ macol. 2009;158(6):1429-41. Epub 2009/10/10.


[247] Urushidate S, Matsuzaka M, Okubo N, Iwasaki H, Hasebe T, Tsuya R, et al. Associa‐ tion between concentration of trace elements in serum and bronchial asthma among Japanese general population. J Trace Elem Med Biol.24(4):236-42.

duced phosphorylation of retinoblastoma protein and checkpoint kinase 1. Br J Phar‐

[235] Knekt P, Kumpulainen J, Jarvinen R, Rissanen H, Heliovaara M, Reunanen A, et al. Flavonoid intake and risk of chronic diseases. The American journal of clinical nutri‐

[236] Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006;71(10):1397-421. Epub 2006/03/28.

[237] Rogerio AP, Dora CL, Andrade EL, Chaves JS, Silva LF, Lemos-Senna E, et al. Antiinflammatory effect of quercetin-loaded microemulsion in the airways allergic in‐

[238] Xie YC, Dong XW, Wu XM, Yan XF, Xie QM. Inhibitory effects of flavonoids extract‐ ed from licorice on lipopolysaccharide-induced acute pulmonary inflammation in

[239] Jung WK, Choi I, Oh S, Park SG, Seo SK, Lee SW, et al. Anti-asthmatic effect of ma‐ rine red alga (Laurencia undulata) polyphenolic extracts in a murine model of asth‐

[240] Watson RR, Zibadi S, Rafatpanah H, Jabbari F, Ghasemi R, Ghafari J, et al. Oral ad‐ ministration of the purple passion fruit peel extract reduces wheeze and cough and improves shortness of breath in adults with asthma. Nutr Res. 2008;28(3):166-71.

[241] Candelario-Jalil E, de Oliveira AC, Graf S, Bhatia HS, Hull M, Munoz E, et al. Resver‐ atrol potently reduces prostaglandin E2 production and free radical formation in lip‐ opolysaccharide-activated primary rat microglia. Journal of neuroinflammation.

[242] Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Re‐ sveratrol improves mitochondrial function and protects against metabolic disease by

activating SIRT1 and PGC-1alpha. Cell. 2006;127(6):1109-22. Epub 2006/11/23.

[243] Zbikowska HM, Wachowicz B, Krajewski T. Selenium compounds inhibit the biolog‐ ical activity of blood platelets. Platelets. 1999;10(2-3):185-90. Epub 2006/06/28.

[244] Horvathova M, Jahnova E, Gazdik F. Effect of selenium supplementation in asthmat‐ ic subjects on the expression of endothelial cell adhesion molecules in culture. Biolog‐

[245] Guo CH, Liu PJ, Hsia S, Chuang CJ, Chen PC. Role of certain trace minerals in oxida‐ tive stress, inflammation, CD4/CD8 lymphocyte ratios and lung function in asthmat‐

[246] Hassan AM. Selenium status in patients with aspirin-induced asthma. Ann Clin Bio‐

ical trace element research. 1999;69(1):15-26. Epub 1999/06/26.

ic patients. Ann Clin Biochem.48(Pt 4):344-51.

macol. 2009;158(6):1429-41. Epub 2009/10/10.

338 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

flammatory model in mice. Pharmacol Res.61(4):288-97.

mice. Int Immunopharmacol. 2009;9(2):194-200.

ma. Food Chem Toxicol. 2009;47(2):293-7.

2007;4:25. Epub 2007/10/12.

chem. 2008;45(Pt 5):508-12.

tion. 2002;76(3):560-8. Epub 2002/08/29.


[271] Bickel D, Roder T, Bestmann HJ, Brune K. Identification and characterization of in‐ hibitors of peptido-leukotriene-synthesis from Petasites hybridus. Planta Med. 1994;60(4):318-22.

[259] Ammon HP, Mack T, Singh GB, Safayhi H. Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of Boswel‐

[260] Gupta I, Gupta V, Parihar A, Gupta S, Ludtke R, Safayhi H, et al. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, place‐

[261] Mynott TL, Ladhams A, Scarmato P, Engwerda CR. Bromelain, from pineapple stems, proteolytically blocks activation of extracellular regulated kinase-2 in T cells. J

[262] Engwerda CR, Andrew D, Ladhams A, Mynott TL. Bromelain modulates T cell and B cell immune responses in vitro and in vivo. Cell Immunol. 2001;210(1):66-75.

[263] Hale LP, Greer PK, Sempowski GD. Bromelain treatment alters leukocyte expression of cell surface molecules involved in cellular adhesion and activation. Clin Immunol.

[264] Secor ER, Jr., Singh A, Guernsey LA, McNamara JT, Zhan L, Maulik N, et al. Brome‐ lain treatment reduces CD25 expression on activated CD4+ T cells in vitro. Int Immu‐

[265] Manhart N, Akomeah R, Bergmeister H, Spittler A, Ploner M, Roth E. Administration of proteolytic enzymes bromelain and trypsin diminish the number of CD4+ cells and the interferon-gamma response in Peyer's patches and spleen in endotoxemic

[266] Secor ER, Jr., Carson WFt, Cloutier MM, Guernsey LA, Schramm CM, Wu CA, et al. Bromelain exerts anti-inflammatory effects in an ovalbumin-induced murine model

[267] Secor ER, Carson WF, Singh A, Pensa M, Guernsey LA, Schramm CM, et al. Oral Bro‐ melain Attenuates Inflammation in an Ovalbumin-induced Murine Model of Asth‐

[268] Szelenyi I, Brune K. Herbal remedies for asthma treatment: between myth and reali‐

[269] Shimoda H, Tanaka J, Yamada E, Morikawa T, Kasajima N, Yoshikawa M. Anti type I allergic property of Japanese butterbur extract and its mast cell degranulation inhib‐

[270] Thomet OA, Wiesmann UN, Blaser K, Simon HU. Differential inhibition of inflam‐ matory effector functions by petasin, isopetasin and neopetasin in human eosino‐

bo-controlled, 6-week clinical study. Eur J Med Res. 1998;3(11):511-4.

lia serrata. Planta Med. 1991;57(3):203-7.

340 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

Immunol. 1999;163(5):2568-75.

nopharmacol. 2009;9(3):340-6.

balb/c mice. Cell Immunol. 2002;215(2):113-9.

ty. Drugs Today (Barc). 2002;38(4):265-303.

phils. Clin Exp Allergy. 2001;31(8):1310-20.

of allergic airway disease. Cell Immunol. 2005;237(1):68-75.

ma. Evid Based Complement Alternat Med. 2008;5(1):61-9.

itory ingredients. J Agric Food Chem. 2006;54(8):2915-20.

2002;104(2):183-90.


[299] Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseas‐ es. Am J Clin Nutr. 2006;83(6 Suppl):1505S-19S.

[284] Biswas S, Rahman I. Modulation of steroid activity in chronic inflammation: a novel anti-inflammatory role for curcumin. Mol Nutr Food Res. 2008;52(9):987-94.

[285] Kurup VP, Barrios CS, Raju R, Johnson BD, Levy MB, Fink JN. Immune response modulation by curcumin in a latex allergy model. Clin Mol Allergy. 2007;5:1.

[286] Ram A, Das M, Ghosh B. Curcumin attenuates allergen-induced airway hyperres‐ ponsiveness in sensitized guinea pigs. Biol Pharm Bull. 2003;26(7):1021-4.

[287] Lee JH, Kim JW, Ko NY, Mun SH, Her E, Kim BK, et al. Curcumin, a constituent of curry, suppresses IgE-mediated allergic response and mast cell activation at the level

[288] Sato H, Goto W, Yamamura J, Kurokawa M, Kageyama S, Takahara T, et al. Thera‐ peutic basis of glycyrrhizin on chronic hepatitis B. Antiviral Res. 1996;30(2-3):171-7.

[289] van Rossum TG, Vulto AG, de Man RA, Brouwer JT, Schalm SW. Review article: gly‐ cyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther.

[290] Sekizawa T, Yanagi K, Itoyama Y. Glycyrrhizin increases survival of mice with her‐

[291] Park HY, Park SH, Yoon HK, Han MJ, Kim DH. Anti-allergic activity of 18beta-gly‐ cyrrhetinic acid-3-O-beta-D-glucuronide. Arch Pharm Res. 2004;27(1):57-60.

[292] Ram A, Mabalirajan U, Das M, Bhattacharya I, Dinda AK, Gangal SV, et al. Glycyr‐ rhizin alleviates experimental allergic asthma in mice. Int Immunopharmacol.

[293] Shin YW, Bae EA, Lee B, Lee SH, Kim JA, Kim YS, et al. In vitro and in vivo antialler‐ gic effects of Glycyrrhiza glabra and its components. Planta Med. 2007;73(3):257-61.

[294] Asl MN, Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and

[295] Hsu CH, Lu CM, Chang TT. Efficacy and safety of modified Mai-Men-Dong-Tang for treatment of allergic asthma. Pediatr Allergy Immunol. 2005;16(1):76-81.

[296] Chan CK, Kuo ML, Shen JJ, See LC, Chang HH, Huang JL. Ding Chuan Tang, a Chi‐ nese herb decoction, could improve airway hyper-responsiveness in stabilized asth‐ matic children: a randomized, double-blind clinical trial. Pediatr Allergy Immunol.

[297] Chang TT, Huang CC, Hsu CH. Clinical evaluation of the Chinese herbal medicine formula STA-1 in the treatment of allergic asthma. Phytother Res. 2006;20(5):342-7.

[298] Wen MC, Wei CH, Hu ZQ, Srivastava K, Ko J, Xi ST, et al. Efficacy and tolerability of anti-asthma herbal medicine intervention in adult patients with moderate-severe al‐

of Syk. J Allergy Clin Immunol. 2008;121(5):1225-31.

342 Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century

pes simplex encephalitis. Acta Virol. 2001;45(1):51-4.

its bioactive compounds. Phytother Res. 2008;22(6):709-24.

lergic asthma. J Allergy Clin Immunol. 2005;116(3):517-24.

1998;12(3):199-205.

2006;6(9):1468-77.

2006;17(5):316-22.

